Medicinal salt of nitrogen-containing bridge heterocyclic derivative, crystal form and preparation method of medicinal salt

Abstract

The invention provides a pharmaceutically acceptable salt of a nitrogen-containing bridge heterocyclic derivative, a crystal form and a preparation method thereof. Specifically, the invention provides different salt forms of 4-((1S, 3S, 5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indole-4-yl) methyl)-8-azabicyclo [3.2. 1] octane-1-yl) benzoic acid, crystal forms of the salts and preparation methods of the salts, and provides a preparation method of the 4-((1S, 3S, 5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indole-4-yl) methyl)-8-azabicyclo [3.2. 1] octane-1-yl) benzoic acid. The crystal form of the salt of (3R, 5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl) methyl)-8-azabicyclo [3.2. 1] octane-1-yl) benzoic acid has good stability, and can be better used for clinical treatment.

Description

A pharmaceutically acceptable salt of a nitrogen-bridged heterocyclic derivative, a crystal form and a preparation method thereof This application claims the priority of Chinese Patent Application No. 2022107702298 filed on June 30, 2022. This application cites the entire text of the above Chinese Patent Application. Technical Field The present invention belongs to the pharmaceutical field and relates to a pharmaceutically acceptable salt and crystal form of a nitrogen-bridged heterocyclic derivative, and specifically, to a pharmaceutically acceptable salt of 4-((1S, 3S, 5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid, and a crystal form and a preparation method thereof. Background Art Complement is a serum protein present in the serum and tissue fluid of humans and vertebrates. It is heat-insensitive and has enzymatic activity after activation. It can mediate immune and inflammatory responses and can be activated by antigen-antibody complexes or microorganisms, leading to the lysis or phagocytosis of pathogenic microorganisms. The complement system is an important regulator of inflammatory response and tissue damage, and is composed of more than 20 serum proteins and cell surface proteins. The complement system includes complement intrinsic components and a variety of regulatory proteins. Complement intrinsic components include C1 to C9, among which C3 has the highest content. Complement regulatory proteins are divided into two categories: soluble and membrane-bound. Soluble complement regulatory proteins include clusterin, S protein, and complement factor H-related protein. Membrane-bound complement regulatory proteins include membrane cofactor protein (MCP), decay accelerating factor (DAF), complement receptor 1, etc. In addition, the complement system also includes some complement fragments and complement receptors, such as C3a receptor, C5a receptor, etc. The complement system is activated through three independent and overlapping pathways, namely the classical pathway (CP), the alternative pathway (AP) and the lectin pathway (LP, also known as the MBL pathway (mannan-binding lectin pathway)). During the complement activation process, a series of positive feedbacks are used to exert a powerful biological effect and participate in the occurrence and development of diseases. C3 convertase is an important component of the first three pathways. It produces a series of complement protein fragments and membrane attack complexes (MAC) through the complement activation cascade reaction. C3 convertase cleaves C3 to generate C5 convertase, which then cleaves C5 to generate C5a and C5b. C5b combines with C6, C7, C8, and C9 to form C5b-9, namely MAC. Abnormalities in the complement pathway can cause the lysis of the body's inherent normal cells, leading to the occurrence of diseases. Complement factor B (Factor B) is a heat-insensitive β-globulin that can be inactivated at 50°C for 30 minutes. It can be cleaved into two fragments, Ba and Bb, by complement factor D. Bb combines with C3b to form the C3 convertase of the alternative pathway. Complement factor B is an important component in the complement alternative activation pathway, also known as the C3 activator precursor. The molecular weight of complement factor B is 93kDa, and the concentration in human blood is about 3μM. It is mainly synthesized in the liver and is also found in the retinal pigment epithelial cells of the eye. Glomerulopathy includes Immunoglobulin A Nephropathy (IgA Nephropathy, IgAN), C3 Glomerulopathy (C3G Glomerulopathy, C3G), Membranous Glomerulonephritis (MGN), etc. Among them, IgAN and MGN are the most common, while the incidence of rare kidney diseases such as C3 glomerulopathy has also increased in the past decade. Studies have found that glomerulopathy is closely related to the complement pathway, especially the complement bypass pathway. Currently There is a lack of effective clinical treatment options for primary glomerulonephritis. Drugs commonly used in treatment include hormones and immunosuppressants (such as cyclophosphamide, mycophenolate mofetil, tacrolimus, cyclosporin A, and the traditional Chinese medicine tripterygium wilfordii polyglycosides). Others include blood pressure control drugs, diuretics, antiplatelet aggregation drugs, anticoagulants, lipid-lowering drugs, cordyceps preparations, and other kidney-protecting and detoxifying drugs. IgAN is the most common primary glomerular disease in the world. Its pathological manifestations are local mesangial proliferation and matrix increase with diffuse mesangial IgA protein deposition, often accompanied by IgG, C3 and C5b-9 deposition. Therefore, it is believed that the complement pathway is related to the occurrence and development of IgAN. Currently, there are two small molecule drugs targeting the complement pathway that are undergoing clinical trials. OMS721 is a humanized monoclonal antibody targeting the MASP-2 protein developed by Omeros. The MASP-2 protein is an effector enzyme that activates the lectin pathway of the complement system. At the end of the Phase 2 clinical trial of OMS721, the proteinuria index of the four IgAN patients participating in the trial was significantly improved. This drug is currently undergoing Phase III clinical trials. Patent applications for Factor B inhibitors disclosed so far include WO2015009616A1, WO2019043609A1, and WO2020016749A2. The application WO2022143845 provides a series of nitrogen-containing heterocyclic derivatives and characterizes their structures, including 4-((1S, 3S, 5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid. In addition, the application also conducted a biological evaluation of 4-((1S, 3S, 5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octane-1-yl)benzoic acid (Compound I), and the results showed that the compound had a good inhibitory effect on Factor B enzyme activity. The crystal structure of active pharmaceutical ingredients often affects the chemical stability of the drug. Different crystallization conditions and storage conditions may lead to changes in the crystal structure of the compound, and sometimes other forms of crystals may be produced. Generally speaking, amorphous drug products do not have regular crystal structures and often have other defects, such as poor product stability, fine crystallization, difficult filtration, easy agglomeration, poor fluidity, etc. Therefore, it is necessary to improve the properties of the above products. We need to conduct in-depth research to find crystals with high crystal purity and good physicochemical stability. Summary of the invention The present disclosure provides a salt of a Factor B inhibitor, a crystal form of the salt, and a preparation method and application thereof. The present disclosure provides a pharmaceutically acceptable salt of Compound I, which is a Factor B inhibitor, and its chemical name is 4-((1S, 3S, 5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octane-1-yl)benzoic acid, and the pharmaceutically acceptable salt is selected from maleate, phosphate, p-toluenesulfonate, sulfate, hydrochloride, fumarate, tartrate, succinate, citrate, malate, methanesulfonate and hydrobromide. In some embodiments, the pharmaceutically acceptable salt of Compound 1 is 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid fumarate. In some embodiments, the pharmaceutically acceptable salt of Compound 1 is 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid-p-toluenesulfonate. In some embodiments, the pharmaceutically acceptable salt of Compound 1 is 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid hydrochloride. In some embodiments, the pharmaceutically acceptable salt of Compound 1 is 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid monophosphate. The present invention provides a method for preparing a pharmaceutically acceptable salt of compound I, comprising 4-((1S, 3S, 5R)-3-ethoxy-8-((5-methyl The step of reacting the acid with an acid selected from the group consisting of maleic acid, phosphoric acid, p-toluenesulfonic acid, sulfuric acid, hydrochloric acid, fumaric acid, tartaric acid, succinic acid, citric acid, malic acid, methanesulfonic acid and hydrobromic acid. In some embodiments, the present disclosure provides a maleate salt I crystalline form of Compound I, having an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, with characteristic peaks at 6.7, 7.6, 8.6, 11.0, 12.1 and 16.2; optionally, having characteristic peaks at 6.7, 7.6, 8.1, 8.6, 11.0, 12.1, 16.2, 19.7 and 23.5; optionally, having characteristic peaks at 6.7, 7.6, 8.1, 8.6, 9.3, 11.0, 12.1, 13.5, 16.2, 17.9, 19.7 and 23.5. In some embodiments, the present disclosure provides a phosphate I crystalline form of Compound I, having an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, with characteristic peaks at 8.4, 10.3, 11.7, 14.8, 19.2 and 21.8; optionally, characteristic peaks at 8.4, 10.3, 11.7, 12.5, 14.8, 19.2, 19.8, 21.8 and 23.9; optionally, characteristic peaks at 7.0, 8.4, 9.3, 10.3, 11.7, 12.5, 14.8, 17.4, 19.2, 19.8, 21.8 and 23.9. In some embodiments, the present disclosure provides a phosphate II crystalline form of Compound I, having an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, with characteristic peaks at 8.4, 9.5, 10.2, 11.7, 14.7 and 19.1; optionally, having characteristic peaks at 6.9, 8.4, 9.5, 10.2, 10.7, 11.7, 14.7, 18.5 and 19.1; optionally, having characteristic peaks at 6.9, 8.4, 8.8, 9.5, 10.2, 10.7, 11.7, 14.7, 15.7, 18.5, 19.1 and 19.8. In some embodiments, the present disclosure provides a phosphate III crystalline form of Compound I, having an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, with characteristic peaks at 7.0, 8.0, 9.8, 11.5, 18.5 and 21.3; optionally, having characteristic peaks at 7.0, 8.0, 9.8, 11.5, 16.1, 18.0, 18.5, 21.3 and 24.1; optionally, having characteristic peaks at 7.0, 8.0, 9.8, 11.5, 16.1, 18.0, 18.5, 20.8, 21.3, 22.9, 24.1 and 25.3. In some embodiments, the present disclosure provides a phosphate IV crystal form of Compound I, having an X-ray powder diffraction pattern represented by a diffraction angle 2θ, with characteristic peaks at 6.9, 8.4, 10.3, 11.7 and 14.8. In some embodiments, the present disclosure provides a phosphate V crystalline form of Compound I, having an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, with characteristic peaks at 9.1, 10.2, 11.5, 15.7 and 19.8; optionally, having characteristic peaks at 8.6, 9.1, 10.2, 11.5, 15.7, 18.0, 19.8 and 23.5. In some embodiments, the present disclosure provides a crystalline form I of a p-toluenesulfonate salt of Compound I, which has an X-ray powder diffraction pattern expressed as a diffraction angle of 2θ, with characteristic peaks at 5.0, 9.4, 10.1, 16.3 and 18.3; optionally, characteristic peaks are present at 5.0, 9.4, 10.1, 16.3, 18.3, 18.9, 21.2 and 22.9; optionally, characteristic peaks are present at 5.0, 9.4, 10.1, 16.0, 16.3, 17.1, 18.3, 18.9, 21.2, 22.9 and 24.0. In some embodiments, the present disclosure provides a crystalline form II of a p-toluenesulfonate salt of Compound I, having an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 4.7, 8.8, 9.3, 10.8, 13.9 and 18.7; optionally, having characteristic peaks at 4.7, 8.8, 9.3, 9.7, 10.8, 13.9, 17.7 and 18.7. In some embodiments, the present disclosure provides a crystalline form III of a p-toluenesulfonate salt of Compound I, which has characteristic peaks at 6.8, 7.4, 8.1, 10.1 and 12.7 in an X-ray powder diffraction pattern represented by a diffraction angle of 2θ. In some embodiments, the present disclosure provides a sulfate salt I crystalline form of Compound I, having an X-ray powder diffraction pattern represented by a diffraction angle 2θ, with characteristic peaks at 7.2, 9.2, 17.1, 20.0, 21.4 and 24.7; optionally, having characteristic peaks at 6.7, 7.2, 9.2, 17.1, 18.7, 20.0, 21.4, 22.9 and 24.7. In some embodiments, the present disclosure provides a sulfate salt II crystalline form of Compound I, wherein the X-ray diffraction angle 2θ is expressed as The X-ray powder diffraction pattern has characteristic peaks at 9.5, 10.2, 16.6, 21.2 and 25.7; optionally, there are characteristic peaks at 6.3, 8.5, 9.5, 10.2, 16.6, 19.8, 21.2, 23.7 and 25.7. In some embodiments, the present disclosure provides a sulfate III crystalline form of Compound I, having an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 6.9, 7.6, 9.1, 18.2 and 23.7; optionally, having characteristic peaks at 6.9, 7.6, 9.1, 17.0, 18.2, 20.7, 23.7 and 24.0. In some embodiments, the present disclosure provides a sulfate IV crystalline form of Compound I, having an X-ray powder diffraction pattern represented by a diffraction angle 2θ, with characteristic peaks at 6.9, 12.5, 16.5, 19.4, 21.2 and 24.0; optionally, having characteristic peaks at 6.9, 9.7, 12.5, 16.5, 19.4, 21.2, 24.0 and 25.8. In some embodiments, the present disclosure provides a sulfate salt V crystalline form of Compound I, having an X-ray powder diffraction pattern represented by a diffraction angle 2θ, with characteristic peaks at 7.6, 11.4, 13.5, 17.2, 18.8 and 19.5; optionally, having characteristic peaks at 7.6, 10.0, 11.4, 13.5, 14.0, 17.2, 19.5, 22.5 and 24.6. In some embodiments, the present disclosure provides a sulfate VI crystalline form of Compound I, having an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 6.7, 8.8, 14.6, 15.9 and 23.7; optionally, having characteristic peaks at 6.7, 8.8, 10.6, 14.6, 15.9, 19.5, 21.4 and 23.7. In some embodiments, the present disclosure provides a hydrochloride salt I crystalline form of Compound I, having an X-ray powder diffraction pattern represented by a diffraction angle 2θ, with characteristic peaks at 5.8, 8.8, 11.6, 20.7 and 23.4; optionally, having characteristic peaks at 5.8, 8.8, 9.8, 10.5, 11.6, 14.6, 18.4, 20.7 and 23.4. In some embodiments, the present disclosure provides a hydrochloride salt II form of Compound I, having an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, with characteristic peaks at 5.9, 8.8, 10.6, 17.2, 19.3 and 23.9; optionally, characteristic peaks at 5.9, 8.8, 10.6, 13.2, 17.2, 19.3, 21.3, 23.9, 24.4 and 26.1; optionally, characteristic peaks at 5.9, 8.8, 10.6, 11.9, 13.2, 14.7, 17.2, 19.3, 19.9, 21.3, 23.9, 24.4, 26.1 and 27.4. In some embodiments, the present disclosure provides a hydrochloride salt III form of Compound I, which has an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, with characteristic peaks at 6.1, 8.8, 10.4, 18.4, 19.9 and 24.6; optionally, it has characteristic peaks at 6.1, 8.8, 10.4, 12.2, 18.4, 19.9, 22.6, 24.6 and 28.0; optionally, it has characteristic peaks at 6.1, 8.8, 10.4, 12.2, 14.6, 16.6, 17.8, 18.4, 19.9, 22.6, 24.6, 27.2 and 28.0. In some embodiments, the present disclosure provides a hydrochloride IV crystalline form of Compound I, with an X-ray powder diffraction pattern expressed as a diffraction angle of 2θ, having characteristic peaks at 5.4, 9.0, 10.8, 20.4 and 21.8; alternatively, there are characteristic peaks at 5.4, 9.0, 10.8, 19.3, 20.4, 21.8 and 27.3. In some embodiments, the present disclosure provides a hydrochloride V crystalline form of Compound I, with an X-ray powder diffraction pattern expressed as a diffraction angle of 2θ, having characteristic peaks at 5.2, 6.7, 7.7, 10.2 and 17.4; alternatively, there are characteristic peaks at 5.2, 6.7, 7.7, 10.2, 10.8, 17.4, 20.5 and 24.2. In some embodiments, the present disclosure provides a hydrochloride salt VI form of Compound I, which has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 5.8, 10.3, 11.7, 17.7, 20.7 and 23.7. In some embodiments, the present disclosure provides a fumarate salt I crystalline form of Compound I, having an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, with characteristic peaks at 9.6, 14.0, 16.7, 19.6, 25.8 and 26.1; optionally, characteristic peaks are present at 6.1, 9.6, 10.0, 14.0, 16.7, 17.2, 19.1, 19.6, 25.8 and 26.1; optionally, characteristic peaks are present at 6.1, 9.6, 10.0, 10.8, 14.0, 16.7, 17.2, 18.6, 19.1, 19.6, 20.2, 25.8 and 26.1. In some embodiments, the present disclosure provides a fumarate II crystalline form of Compound I, represented by a diffraction angle 2θ. The X-ray powder diffraction pattern has characteristic peaks at 6.2, 6.6, 8.0, 13.2, 14.0, 20.3 and 24.2; optionally, there are characteristic peaks at 6.2, 6.6, 8.0, 9.0, 13.2, 14.0, 16.4, 17.1, 19.8, 20.3, 24.2 and 25.3; optionally, there are characteristic peaks at 6.2, 6.6, 8.0, 9.0, 12.0, 13.2, 14.0, 16.4, 17.1, 19.3, 19.8, 20.3, 21.9, 22.3, 24.2, 25.3, 25.7 and 28.1. In some embodiments, the present disclosure provides a hydrobromide salt I crystalline form of Compound I, which has an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, with characteristic peaks at 7.6, 10.6, 16.4, 18.4, 22.6 and 24.0; optionally, characteristic peaks are present at 7.6, 10.6, 15.3, 16.4, 18.4, 19.6, 22.6, 24.0, 26.5 and 27.0; optionally, characteristic peaks are present at 7.6, 10.6, 15.3, 16.4, 18.4, 19.6, 21.4, 22.6, 24.0, 25.5, 26.5, 27.0 and 28.9. In some embodiments, the present disclosure provides a hydrobromide salt II crystalline form of Compound I, having an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, with characteristic peaks at 7.2, 10.5, 16.5, 22.5, 23.4 and 26.6; optionally, having characteristic peaks at 7.2, 10.5, 13.1, 16.5, 18.8, 20.3, 22.5, 23.4 and 26.6; optionally, having characteristic peaks at 7.2, 10.5, 13.1, 16.5, 17.2, 18.8, 20.3, 21.5, 21.9, 22.5, 23.4 and 26.6. In some embodiments, the present disclosure provides an amorphous maleate salt of Compound I, whose X-ray powder diffraction pattern has no obvious characteristic peaks within the diffraction angle 2θ range of 3-48°. In some embodiments, the present disclosure provides an amorphous phosphate of Compound I, whose X-ray powder diffraction pattern has no obvious characteristic peak at a diffraction angle 2θ in the range of 3-48°. In some embodiments, the present disclosure provides an amorphous p-toluenesulfonate salt of Compound I, whose X-ray powder diffraction pattern has no obvious characteristic peak at a diffraction angle 2θ in the range of 3-48°. In some embodiments, the present disclosure provides an amorphous sulfate salt of Compound I, whose X-ray powder diffraction pattern has no obvious characteristic peaks within the diffraction angle 2θ range of 3-48°. In some embodiments, the present disclosure provides an amorphous tartrate salt of Compound I, whose X-ray powder diffraction pattern has no obvious characteristic peak at a diffraction angle 2θ in the range of 3-48°. In some embodiments, the present disclosure provides an amorphous succinate salt of Compound I, whose X-ray powder diffraction pattern has no obvious characteristic peaks within the diffraction angle 2θ range of 3-48°. In some embodiments, the present disclosure provides an amorphous fumarate salt of Compound I, whose X-ray powder diffraction pattern has no obvious characteristic peak at a diffraction angle 2θ in the range of 3-48°. In some embodiments, the present disclosure provides an amorphous citrate salt of Compound I, whose X-ray powder diffraction pattern has no obvious characteristic peak at a diffraction angle 2θ in the range of 3-48°. In some embodiments, the present disclosure provides an amorphous malate salt of Compound I, whose X-ray powder diffraction pattern has no obvious characteristic peaks within the diffraction angle 2θ range of 3-48°. In some embodiments, the present disclosure provides an amorphous hydrobromide salt of Compound I, whose X-ray powder diffraction pattern has no obvious characteristic peak at a diffraction angle 2θ in the range of 3-48°. In some embodiments, the present disclosure provides an amorphous mesylate salt of Compound I, whose X-ray powder diffraction pattern has no obvious characteristic peak at a diffraction angle 2θ in the range of 3-48°. In some embodiments, the present disclosure provides an amorphous hydrochloride salt of Compound I, whose X-ray powder diffraction pattern has no obvious characteristic peak at a diffraction angle 2θ in the range of 3-48°. In an optional embodiment, the present disclosure provides a crystalline form of a pharmaceutically acceptable salt of Compound I, wherein the 2θ angle The error range is ±0.2. On the other hand, the present disclosure provides a method for preparing a maleate salt I crystalline form of Compound I, comprising: a. dissolving Compound I in acetonitrile, adding maleic acid solution for slurrying, and b. adding isopropyl ether for crystallization. The present disclosure provides a method for preparing a phosphate I crystal form of compound I, comprising adding compound I to a solvent (1) and phosphoric acid, stirring and crystallizing, wherein the solvent (1) is selected from acetonitrile and acetone. The present disclosure provides a method for preparing a phosphate II crystal form of compound I, comprising adding compound I to a solvent (2) and phosphoric acid, stirring and crystallizing, wherein the solvent (2) is selected from ethyl acetate and acetone. The present disclosure provides a method for preparing a phosphate III crystal form of compound I, comprising adding compound I to a solvent (3) and phosphoric acid, stirring and crystallizing, wherein the solvent (3) is selected from isopropanol and ethanol. The present disclosure provides a method for preparing a phosphate IV crystal form of a compound I, comprising adding the compound I to acetonitrile and phosphoric acid, and stirring to crystallize. The present disclosure provides a method for preparing a phosphate V crystal form of a compound I, comprising adding the compound I to ethanol and phosphoric acid, and stirring to crystallize. The present disclosure provides a method for preparing a p-toluenesulfonate salt I crystalline form of compound I, comprising method 1: adding compound I to a solvent (4) and p-toluenesulfonic acid, slurrying at room temperature, adding isopropyl ether and stirring for crystallization, wherein the solvent (4) is selected from ethanol, isopropanol, and ethyl acetate; method 2: adding compound I to acetonitrile and p-toluenesulfonic acid, and stirring for crystallization. The present disclosure provides a method for preparing a p-toluenesulfonate II crystal form of a compound I, comprising adding isopropanol and p-toluenesulfonic acid to the compound I, and stirring to crystallize. The present disclosure provides a method for preparing a p-toluenesulfonate III crystal form of compound I, comprising adding p-toluenesulfonate II crystal form to methyl tert-butyl ether and stirring for crystallization. The present disclosure provides a method for preparing a crystal form of compound I sulfate salt I, comprising adding compound I to a solvent (5) and sulfuric acid, stirring and crystallizing, wherein the solvent (5) is selected from ethanol and acetonitrile. The present disclosure provides a method for preparing a sulfate II crystal form of a compound I, comprising adding the compound I to acetone and sulfuric acid, and stirring to crystallize. The present disclosure provides a method for preparing a sulfate III crystal form of compound I, comprising dissolving compound I in ethanol, adding sulfuric acid, and adding isopropyl ether for stirring and crystallization. The present disclosure provides a method for preparing a sulfate IV crystal form of compound I, comprising adding compound I to a solvent (6) and sulfuric acid, stirring and crystallizing, wherein the solvent (6) is selected from isopropanol and acetone. The present disclosure provides a method for preparing a sulfate salt V crystal form of compound I, comprising adding compound I to a solvent (7) and sulfuric acid, stirring and crystallizing, wherein the solvent (7) is selected from ethyl acetate and isopropyl acetate. The present disclosure provides a method for preparing a sulfate VI crystal form of compound I, comprising adding sulfate I crystal form to isopropyl acetate and stirring to crystallize. The present disclosure provides a method for preparing a hydrochloride salt I crystal form of a compound I, comprising method 1: dissolving the compound I in ethanol and hydrochloric acid, adding isopropyl ether, and stirring to crystallize; method 2: adding isopropyl acetate and hydrochloric acid to the compound I, and stirring to crystallize. The present disclosure provides a method for preparing a hydrochloride II crystal form of compound I, comprising: method 1: dissolving compound I in ethanol, adding hydrochloric acid, and adding isopropyl ether for stirring and crystallization; method 2: adding compound I to a solvent (8) and hydrochloric acid, stirring and crystallizing, wherein the solvent (8) is selected from isopropanol and acetonitrile. The present disclosure provides a method for preparing a hydrochloride III crystal form of compound I, comprising adding compound I to a solvent (9) and hydrochloric acid, stirring and crystallizing, wherein the solvent (9) is selected from acetone and ethyl acetate. The present disclosure provides a method for preparing a hydrochloride IV crystal form of compound I, comprising adding compound I to a solvent (10) of hydrochloric acid, and stirring to crystallize; the solvent (10) is selected from tetrahydrofuran and isopropanol. The present disclosure provides a method for preparing a hydrochloride V crystal form of a compound I, comprising adding acetonitrile and hydrochloric acid to the compound I, and stirring to crystallize. The present disclosure provides a method for preparing a hydrochloride VI crystal form of a compound I, comprising adding isopropanol and hydrochloric acid to the compound I, and stirring to crystallize. The present disclosure provides a method for preparing a fumarate salt I crystalline form of compound I, comprising adding compound I to a solvent (11) and fumaric acid, and stirring for crystallization; the solvent (11) is selected from acetonitrile and acetone. The present disclosure provides a method for preparing a crystal form of a fumarate salt of a compound I, comprising adding the compound I to a methanol / acetonitrile solution and fumaric acid, and volatilizing and crystallizing. The present disclosure provides a method for preparing a hydrobromide salt I crystal form of compound I, comprising dissolving compound I in ethanol, adding hydrobromic acid, and adding isopropyl ether for stirring and crystallization. The present disclosure provides a method for preparing a hydrobromide II crystalline form of compound I, comprising adding compound I to a solvent (12) and hydrobromic acid, stirring and crystallizing, wherein the solvent (12) is selected from isopropanol and ethyl acetate. The present disclosure provides a method for preparing an amorphous maleate salt of Compound I, comprising dissolving Compound I in a solvent (13) and maleic acid, then adding isopropyl ether, stirring and crystallizing, wherein the solvent (13) is selected from at least one of ethanol, acetone, tetrahydrofuran, acetonitrile / methanol, isopropanol, and ethyl acetate. The present disclosure provides a method for preparing an amorphous phosphate of compound I, comprising: method 1: dissolving compound I in acetonitrile / methanol and phosphoric acid, slurrying at room temperature, then adding isopropyl ether, and stirring to crystallize; method 2: adding compound I to a solvent (14) and phosphoric acid, stirring to crystallize, wherein the solvent (14) is selected from ethanol and tetrahydrofuran. The present disclosure provides a method for preparing an amorphous p-toluenesulfonate salt of Compound I, comprising adding Compound I to a solvent (15) and p-toluenesulfonic acid, slurrying at room temperature, then adding isopropyl ether, stirring and crystallizing, wherein the solvent (15) is selected from at least one of acetonitrile, acetone, tetrahydrofuran or acetonitrile / methanol. The present disclosure provides a method for preparing an amorphous sulfate salt of Compound I, comprising: Method 1: dissolving Compound I in acetonitrile / methanol, adding sulfuric acid, slurrying at room temperature, and then adding isopropyl ether for crystallization; Method 2: adding tetrahydrofuran and sulfuric acid to Compound I for crystallization. The present disclosure provides a method for preparing an amorphous tartrate salt of Compound I, comprising: Method 1: dissolving Compound I in a solvent (16), adding tartaric acid, slurrying at room temperature, then adding isopropyl ether, and crystallizing, wherein the solvent (16) is selected from ethanol or tetrahydrofuran; Method 2: adding Compound I to a solvent (17) and tartaric acid, and crystallizing, wherein the solvent (17) is selected from acetonitrile or acetone. The present disclosure provides a method for preparing an amorphous succinate salt of Compound I, comprising: Method 1: dissolving Compound I in a solvent (18), adding succinic acid, slurrying at room temperature, then adding isopropyl ether, and crystallizing, wherein the solvent (18) is selected from ethanol or tetrahydrofuran; Method 2: adding Compound I to a solvent (19) and succinic acid, and crystallizing, wherein the solvent (19) is selected from acetonitrile or acetone. The present disclosure provides a method for preparing an amorphous fumarate salt of Compound I, comprising: Method 1: dissolving Compound I in a solvent (20), adding fumaric acid, slurrying at room temperature, and then adding isopropyl ether to crystallize, wherein the solvent (20) is selected from ethanol or tetrahydrofuran; Method 2: adding acetone and fumaric acid to Compound I to crystallize. The present disclosure provides a method for preparing an amorphous citrate of Compound I, comprising dissolving Compound I in a solvent (21), adding citric acid, slurrying at room temperature, then adding isopropyl ether, and crystallizing, wherein the solvent (21) is selected from at least one of ethanol, acetonitrile, acetone or tetrahydrofuran. The present disclosure provides a method for preparing an amorphous malate salt of Compound I, comprising: Method 1: dissolving Compound I in a solvent (22), adding malic acid, slurrying at room temperature, and then adding isopropyl ether to crystallize, wherein the solvent (22) is selected from at least one of ethanol, acetone or tetrahydrofuran; Method 2: adding acetonitrile and malic acid to Compound I to crystallize. The present disclosure provides a method for preparing an amorphous hydrobromide salt of Compound I, comprising dissolving Compound I in a solvent (23) of acetonitrile, adding hydrobromic acid, slurrying at room temperature, and then adding isopropyl ether to crystallize; the solvent (23) is selected from at least one of acetonitrile, acetone or tetrahydrofuran. The present disclosure provides a method for preparing an amorphous methanesulfonate salt of Compound I, comprising dissolving Compound I in a solvent (24), adding methanesulfonic acid, slurrying at room temperature, then adding isopropyl ether, and crystallizing, wherein the solvent (24) is selected from at least one of acetonitrile, acetone, tetrahydrofuran or ethanol. The present disclosure provides a method for preparing an amorphous hydrochloride of Compound I, comprising dissolving Compound I in ethanol, adding hydrochloric acid, slurrying at room temperature, and then adding isopropyl ether for crystallization. In certain embodiments, the method for preparing the crystalline form described in the present disclosure further comprises a filtering, washing or drying step. The present disclosure also provides a pharmaceutical composition prepared from the crystalline form of the pharmaceutically acceptable salt of the aforementioned Compound I. The present disclosure also provides a pharmaceutical composition comprising a pharmaceutically acceptable salt of the aforementioned Compound I, a crystalline form of the pharmaceutically acceptable salt, or a mixture thereof, or a pharmaceutically acceptable salt of the Compound I, a crystalline form of the pharmaceutically acceptable salt prepared by the aforementioned method, and optionally a pharmaceutically acceptable excipient. The present disclosure also provides a method for preparing a pharmaceutical composition, comprising the step of mixing the pharmaceutically acceptable salt of the aforementioned compound I, a crystalline form of the pharmaceutically acceptable salt, or a mixture thereof, or the pharmaceutically acceptable salt of the compound I, a crystalline form of the pharmaceutically acceptable salt prepared by the aforementioned method, with a pharmaceutically acceptable excipient. The present disclosure also provides a pharmaceutically acceptable salt of Compound I, a crystalline form of a pharmaceutically acceptable salt, or a mixture thereof, or a pharmaceutically acceptable salt, a crystalline form of a pharmaceutically acceptable salt, or a mixture thereof prepared by the aforementioned method, or the aforementioned composition, or use of a composition prepared by the aforementioned method in the preparation of a medicament for inhibiting activation of the complement alternative pathway. The present disclosure also provides a pharmaceutically acceptable salt of Compound I, a crystalline form of a pharmaceutically acceptable salt, or a mixture thereof, or a pharmaceutically acceptable salt, a crystalline form of a pharmaceutically acceptable salt, or a mixture thereof prepared by the aforementioned method, or a use of the aforementioned composition in preparing a medicament for treating a disease or condition, wherein the disease or condition is selected from glomerulopathy, hemolytic uremic syndrome, atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, geographic atrophy, diabetic retinopathy, uveitis, pigmentary retinitis, macular edema, uveitis caused by Behcet's syndrome, multifocal choroiditis, Fu-Koyanagi-Harada syndrome, shotgun retinochoroiditis, sympathetic ophthalmia, ocular cicatricial pemphigoid, ocular pemphigus , nonarteritic ischemic optic neuropathy, postoperative inflammation, retinal vein occlusion, neurological disorders, multiple sclerosis, stroke, Guillain-Barré syndrome, traumatic brain injury, Parkinson's disease, inappropriate or undesired complement activation disorders, complications of hemodialysis, hyperacute allograft rejection, xenograft rejection, interleukin-2-induced toxicity during IL-2 therapy, Crohn's disease, adult respiratory distress syndrome, myocarditis, post-ischemic reperfusion disorder, myocardial infarction, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass surgery or renal bypass surgery, atherosclerosis, hemodialysis, renal ischemia, aortic reconstruction, mesenteric artery reperfusion after infectious disease or sepsis, systemic lupus erythematosus, Systemic lupus erythematosus nephritis, proliferative nephritis, liver fibrosis, hemolytic anemia, myasthenia gravis, tissue regeneration, nerve regeneration, dyspnea, hemoptysis, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, emphysema, pulmonary embolism and infarction, pneumonia, fibrosing dust disease, pulmonary fibrosis, asthma, allergy, bronchoconstriction, parasitic diseases, Goodman syndrome, pulmonary vasculitis, pauci-immune vasculitis, immune complex-associated inflammation, antiphospholipid syndrome and obesity; the disease or condition is preferably C3 glomerulopathy, immunoglobulin A nephropathy, membranous glomerulonephritis, atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. The "2θ or 2θ angle" mentioned in the present disclosure refers to the diffraction angle, θ is the Bragg angle, and the unit is ° or degree; the error range of each characteristic peak 2θ is ±0.20 (including the case where the number exceeding 1 decimal place is rounded off), specifically -0.20, -0.19, -0.18, -0.17, -0.16, -0.15, -0.14, -0.13, -0.12, -0.11, -0.10, -0.09, -0.08, -0.07, -0.06, -0.05, -0.04, -0.03, -0.02, -0.01, 0.00, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20. The "crystallization" or "crystallization" described in the present disclosure includes but is not limited to stirring crystallization, slurry crystallization, cooling crystallization and volatile crystallization. The "differential scanning calorimetry or DSC" described in the present disclosure refers to measuring the temperature difference and heat flow difference between a sample and a reference object during the process of heating or maintaining a constant temperature of the sample to characterize all physical and chemical changes related to thermal effects and obtain phase change information of the sample. The drying temperature in the present disclosure is generally 25° C.-100° C., preferably 40° C.-70° C., and the drying can be performed under normal pressure or reduced pressure. The "pharmaceutically acceptable excipients" described in the present disclosure include, but are not limited to, any adjuvant, carrier, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent or emulsifier approved by the U.S. Food and Drug Administration for use by humans or livestock animals. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is an XRPD spectrum of Compound 1 maleate salt Form 1. Figure 2 is the XRPD spectrum of Compound I Phosphate I Crystalline Form. Figure 3 is the XRPD spectrum of Compound I phosphate II crystal form. FIG4 is an XRPD spectrum of Compound I phosphate III crystal form. FIG5 is an XRPD spectrum of Compound I phosphate IV crystal form. FIG6 is an XRPD spectrum of Compound I Phosphate Form V. Figure 7 is the XRPD spectrum of Compound 1 p-toluenesulfonate salt Form 1. FIG8 is an XRPD spectrum of Compound I p-toluenesulfonate salt Form II. FIG9 is an XRPD spectrum of Compound I p-toluenesulfonate salt Form III. Figure 10 is the XRPD spectrum of Compound 1 Sulfate Form 1. Figure 11 is the XRPD spectrum of Compound I sulfate II crystal form. Figure 12 is the XRPD spectrum of Compound I sulfate III crystal form. Figure 13 is the XRPD spectrum of Compound I sulfate IV crystal form. Figure 14 is an XRPD spectrum of Compound I sulfate Form V. Figure 15 is the XRPD spectrum of Compound I sulfate VI crystal form. Figure 16 is the XRPD spectrum of Compound 1 Hydrochloride Form 1. Figure 17 is the XRPD spectrum of Compound I hydrochloride Form II. Figure 18 is the XRPD spectrum of Compound I hydrochloride Form III. Figure 19 is the XRPD spectrum of Compound I hydrochloride Form IV. Figure 20 is the XRPD spectrum of Compound I hydrochloride Form V. Figure 21 is the XRPD spectrum of Compound I hydrochloride Form VI. Figure 22 is the XRPD spectrum of Compound 1 fumarate salt Form 1. Figure 23 is the XRPD spectrum of Compound I fumarate salt Form II. Figure 24 is the XRPD spectrum of Compound 1 hydrobromide salt Form 1. Figure 25 is the XRPD spectrum of Compound I hydrobromide salt Form II. Figure 26 is the XRPD spectrum of Compound I fumarate amorphous form. DETAILED DESCRIPTION The present disclosure is further described in detail by the following examples and experimental examples. These examples and experimental examples are only for illustrative purposes and are not intended to limit the scope of the present disclosure. Test conditions of the instruments used in the experiment: The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10-6 The unit of (ppm) is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer, with deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD) as the measuring solvent, and tetramethylsilane (TMS) as the internal standard. MS was measured using a FINNIGAN LCQAd (ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQ advantage MAX). HPLC analysis was performed using an Agilent 1260DAD high pressure liquid chromatograph (Sunfire C18 150×4.6 mm column) and a Thermo U3000 high pressure liquid chromatograph (Gimini C18 150×4.6 mm column). XRPD is X-ray powder diffraction detection: the measurement is carried out using a BRUKER D8 X-ray diffractometer, specific collection information: Cu anode (40kV, 40mA), ray: monochromatic Cu-Ka ray Scanning mode: θ / 2θ, scanning range: 3-48°. DSC is differential scanning calorimetry: the measurement was performed using a METTLER TOLEDO DSC 3+ differential scanning calorimeter with a heating rate of 10°C / min, 25-350°C, and a nitrogen purge rate of 50 mL / min. TGA is thermogravimetric analysis: the test was performed using a METTLER TOLEDO TGA 2 thermogravimetric analyzer with a heating rate of 10°C / min, the specific temperature range refers to the corresponding spectrum, and the nitrogen purge rate is 50 mL / min. DVS is dynamic moisture adsorption: using Surface Measurement Systems instrinsic, humidity starts from 50%, the humidity range is 0%-95%, the step is 10%, the judgment standard is that the mass change dM / dT of each gradient is less than 0.002%, TMAX is 360min, and it is cycled twice. Example 1. Preparation of Compound I (refer to the preparation method of Examples 1-2 in application number PCT / CN2021 / 142760) first step 1-(4-Bromophenyl)butane-1,4-diol 1b Dissolve methyl 4-(4-bromophenyl)-4-oxobutanoate 1a (5 g, 17.54 mmol, Bid Pharmaceutical Technology Co., Ltd.) in tetrahydrofuran (50 mL), add lithium borohydride tetrahydrofuran solution (17 mL, 2 mmol / mL) at 0°C, naturally warm to room temperature, and stir overnight. The reaction solution was quenched with saturated sodium thiosulfate solution and extracted with ethyl acetate. The organic phase was dried and concentrated to obtain the crude title product 1b (4.29 g), which was directly used in the next step without purification. MS m / z(ESI):242.9[MH]. Step 2 4-(4-Bromophenyl)-4-oxobutyraldehyde 1c Dissolve dimethyl sulfoxide (8.2 g, 104.95 mmol) in dichloromethane (50 mL), add oxalyl chloride (8.8 g, 69.33 mmol) at -78 °C, continue stirring for 10 minutes, add compound 1b (4.29 g, 17.50 mmol), and add triethylamine (17.7 g, 174.92 mmol). The reaction solution was stirred for 1 hour. The temperature was naturally raised to room temperature, diluted with dichloromethane, and the organic phase was washed with a saturated aqueous sodium bicarbonate solution. The organic phase was dried, concentrated under reduced pressure, and purified by silica gel column chromatography with eluent C to obtain the title compound 1c (2.7 g, yield: 64%). MS m / z(ESI):240.8[M+1]. Step 3 1-(4-Bromophenyl)-8-[(4-methoxybenzyl)-8-azabicyclo[3.2.1]octan-3-one 1d Dissolve 4-methoxybenzylamine (1.61 g, 11.74 mmol, Shaoyuan Technology Co., Ltd.) and sodium acetate (6.43 g, 78.38 mmol) in water (7.5 mL), add 2M hydrochloric acid (16 mL) and 1,3-acetone dicarboxylic acid (1.96 g, 13.42 mmol) at 0°C, continue stirring for 30 minutes, add compound 1c (2.7 g, 11.20 mmol), and stir at 40°C for 3 hours after 30 minutes. The reaction solution is adjusted to pH 8-9 with saturated sodium bicarbonate solution, and extracted with ethyl acetate. The organic phase is dried, concentrated under reduced pressure, and purified by silica gel column chromatography with eluent C to obtain the title compound 1d (580 mg, yield: 12.9%). MS m / z(ESI):399.9[M+1]. Step 4 1-(4-Bromophenyl)-8-(4-methoxybenzyl)-8-azabicyclo[3.2.1]octan-3-ol 1e Compound 1d (530 mg, 1.32 mmol) was dissolved in methanol (5 mL), and sodium borohydride (200 mg, 5.29 mmol) was added. The mixture was stirred at room temperature for 2 hours. The reaction solution was quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic phase was dried and concentrated under reduced pressure to give the crude title compound 1e (420 mg, yield: 78.8%). MS m / z(ESI):401.8[M+1]. Step 5 1-(4-Bromophenyl)-3-ethoxy-8-(4-methoxybenzyl)-8-azabicyclo[3.2.1]octane 1f Compound 1e was dissolved in dimethylformamide (5 mL), and sodium hydride (83 mg, 2.08 mmol) was added at 0°C. The reaction solution was stirred for 1 hour, and iodoethane (325 mg, 2.09 mmol) was added. The reaction solution was warmed to room temperature and stirred overnight. The reaction solution was quenched with saturated aqueous ammonium chloride solution, extracted with ethyl acetate, and the organic phase was dried, concentrated under reduced pressure, and purified by silica gel column chromatography with eluent C to obtain the title compound 1f (350 mg, yield: 77.9%). MS m / z(ESI):429.9[M+1]. Step 6 4-(3-ethoxy-8-(4-methoxybenzyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid methyl ester 1g Compound 1f was dissolved in methanol (4 mL) and dimethylformamide (4 mL), and palladium acetate (54 mg, 240.52 μmol), diphenylphosphoryl azide (100 mg, 242.46 μmol) and triethylamine (822 mg, 8.12 mmol) were added. Carbon monoxide gas was replaced three times and stirred at 80°C overnight. The reaction solution was poured into water, extracted with ethyl acetate, the organic phase was dried, concentrated under reduced pressure, and purified by silica gel column chromatography with eluent C to obtain the title compound 1g (225 mg, yield: 67.5%). MS m / z(ESI):411.0[M+1]. Step 7 Methyl 4-(3-ethoxy-8-azabicyclo[3.2.1]octan-1-yl)benzoate 1h Dissolve compound 1g (225mg, 549.43μmol) in ethanol (5mL), add palladium carbon hydrogenation catalyst (40mg, 375.87μmol). Replace with hydrogen three times, stir at room temperature for 48 hours under hydrogen atmosphere. Filter the reaction solution, and concentrate the organic phase under reduced pressure to obtain the crude title compound 1h (130mg), which is used directly in the next step without purification. MS m / z(ESI):290.0[M+1]. Step 8 tert-Butyl 4-(bromomethyl)-5-methoxy-7-methylindole-1-carboxylate 1j Compound 4-(hydroxymethyl)-5-methoxy-7-methyl-1H-indole-1-carboxylic acid tert-butyl ester 1i (150 mg, 514.86 μmol, synthesized by referring to the preparation method of intermediate 1-10 of WO2015009616A1) was dissolved in dichloromethane (2 mL), and carbon tetrabromide (170 mg, 512.62 μmol) and triphenylphosphine (135 mg, 514.71 μmol) were added under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 2 hours and directly concentrated to obtain a crude compound 1j (183 mg). The product was directly used in the next step without purification. Step 9 4-((3-ethoxy-1-(4-(methoxycarbonyl)phenyl)-8-azabicyclo[3.2.1]octan-8-yl)methyl)-5-methoxy-7-methyl-1H-indole-1-carboxylic acid tert-butyl ester 1k Compound 1h (100 mg, 345.5801 μmol) was dissolved in dimethylformamide (2 mL), and sodium hydride (27 mg, 675.07 μmol) was added at 0°C. The reaction solution was stirred for 1 hour, and then a dimethylformamide solution of compound 1j (183 mg, 516.60 μmol) was added, and the reaction solution was stirred for 1 hour, quenched with saturated aqueous ammonium chloride solution, and the organic phase was dried, concentrated under reduced pressure, and purified by silica gel column chromatography with eluent C to obtain the title compound 1k (130 mg, yield: 66.8%). MS m / z(ESI):563.0[M+1]. Step 10 (±)-rel-4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid 1 Compound 1k (130 mg, 231.03 μmol) was dissolved in 6 mL of a mixed solution of tetrahydrofuran, methanol and water (V:V:V=1:1:1). Lithium hydroxide monohydrate (58 mg, 1.38 mmol) was added. The reaction solution was stirred at 70°C for 3 hours. The reaction solution was concentrated, diluted with a small amount of methanol, and purified by high performance liquid chromatography (Waters 2545, chromatographic column: Sharpsil-T C18, 250*50 mm, 8 μm; mobile phase A: water (containing 10 mmol / L ammonium bicarbonate); mobile phase B: acetonitrile; 18-minute gradient: 20%-38%, flow rate: 80 mL / min) to obtain the title compounds 1 (4 mg, yield: 3.86%) and 2 (5 mg, yield: 4.82%). Compound 1: High performance liquid chromatography: retention time 17.28min. MS m / z(ESI):449.1[M+1]. 1 H NMR (500 MHz, CD 3 OD): δ8.16-8.14 (m, 2H), 7.69 (br, 2H), 7.35-7.34 (m, 1H), 6.84 (s, 1H), 6.34 (br, 1H), 4.20-4.03 (m, 3H), 3.93 (s, 3H), 3.7 1-3.58 (m, 1H), 3.51-3.34 (m, 2H), 3.32-2.96 (m, 2H), 2.73-2.68 (m, 3H), 2.54 (s, 3H), 2.25-2.04 (m, 3H), 1.25-1.22m, 3H). Compound 1 (100 mg, 222.93 μmol) was subjected to chiral preparation (separation conditions: chiral preparation column CHIRALPAK IG, 5μm, 20mm*250mm (Phenomenex); mobile phase 1: n-hexane (80%); mobile phase 2: containing 0.1% diethylamine, 0.1% trifluoroacetic acid, ethanol (20%), flow rate: 20mL / min. Purify, collect the corresponding components, and concentrate under reduced pressure to obtain the title compounds 1-1 (35mg, yield: 35%) and 1-2 (33mg, yield: 33%). Compound 1-1 (Compound I, 4-((1S, 3S, 5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid): MS m / z (ESI): 449.1 [M+1]. Chiral HPLC analysis: retention time 7.946 minutes, chiral purity: 100% (chromatographic column: CHIRALPAK IG, 5μm, 20mm*250mm (Phenomenex); mobile phase 1: n-hexane (80%); mobile phase 2: containing 0.1% diethylamine, 0.1% trifluoroacetic acid, ethanol (20%), flow rate: 1mL / min). 1 H NMR (500MHz, MeOD) δ 8.16-8.15 (m, 2H), 7.69 (br, 2H), 7.34 (br, 1H), 6.83 (s, 1H), 6.33 (br, 1H), 4.22-4.12 (m, 2H), 4.03-4.00 (m, 1H), 3.9 3(s, 3H), 3.71-3.51(m, 1H), 3.50-3.35(m, 2H), 3.32-2.96(m, 2H), 2.73-2.53(m, 3H), 2.51(s, 3H), 2.21-2.05(m, 3H), 1.35-1.22(m, 3H). Example 2. Inhibitory effect of compound I on Factor B enzymatic activity 1. Experimental Materials and Instruments 1. Recombinant human complement factor B protein (expressed by Nanjing GenScript Biotechnology Co., Ltd.) 2. Recombinant human complement factor D protein (1824-SE-010, R&D system) 3. Human complement factor C3 (204885-250UGCN, EMDmillipore) 4. Cobra venom factor (CVF) (A600, Quidel) 5.StartingBlock TM T20 (TBS) blocking buffer (37543, Thermo Fisher) 6. Goat anti-mouse IgG heavy chain + light chain (horseradish peroxidase labeled) (ab205719, Abcam) 7. Anti-C3a / C3a des Arg antibody clone number

[2991] (ab11873, Abcam) 8. QuantaBlu TM Fluorescent peroxidase substrate kit (15169, Thermo Fisher) 9. Amphoteric surfactant (CHAPS) (C3023, Sigma) 10. Magnesium chloride solution (M1028-100ML, Sigma) 11. Sodium carbonate 2 CO 3 (10019260, Shanghai test) 12. Sodium bicarbonate NaHCO 3 (10018960, Shanghai test) 13. Tween 20 (P7949-500ML, Sigma) 14. 20X PBS buffer (B548117-0500, Biotech) 15. 96-well white half-well plate (66PL96025, Cisbio) 16. 96-well black adsorption plate (437111, Thermo Fisher) 17. Phosphate buffer (B320, Shanghai Yuanpei Biotechnology Co., Ltd.) 18. Sterile pure water (made by Shanghai Hengrui) 19. 96-well dispensing plate (3795, Corning) 20. Constant temperature box (Shanghai Yiheng Scientific Instrument Co., Ltd.) 21.Flexstation3 microplate reader (Molecular Device) 2. Experimental steps Human complement factor B protein needs to form a complex with human complement factor C3 to exert its protease function. Under the hydrolysis of protein, human complement factor B is hydrolyzed into Ba and Bb fragments. Bb forms a complex C3bBb with the C3b fragment of human complement factor C3, i.e., C3 convertase. The formation of this complex allows human complement factor B to play the protease function. C3bBb continues to hydrolyze C3 into C3a and C3b fragments. C3b and C3bBb form a complex C3bBbC3b, i.e., C5 convertase, and the C3a fragment is released. By detecting the C3a des Arg epitope generated after C3 is cleaved, it can be used to evaluate the efficiency of C3 hydrolysis, i.e., C3bBb enzyme activity, so as to evaluate the effect of the compound on C3bBb enzyme. Since C3b is unstable in vitro, cobra venom factor (hereinafter referred to as CVF) is used instead of C3b to form a complex with human complement factor B, and its function is the same as C3b. The gene encoding the amino acid AA128-2422 of human complement factor B protein (NM_001710.6) was codon-optimized, gene-synthesized, cloned into the pcDNA3.4 vector, and expressed and purified in HD CHO-S cells by Nanjing GenScript Biotechnology Co., Ltd. The purified recombinant human complement factor B protein was stored in a -80°C refrigerator after aliquoting. Human complement factor B protein cleavage reaction: dilute the recombinant human complement factor D protein 10 times with PBS (pH 7.4) and store on ice until use. 2 , 0.05% CHAPS) was added with recombinant human complement factor D protein at a final concentration of 300 nM, 1 μM recombinant human complement factor B protein and 1 μM CVF, mixed thoroughly, and reacted in a 37°C incubator for 3 hours to obtain a complex of CVF and sheared recombinant human complement factor B protein fragment Bb (hereinafter referred to as CVF:Bb). Preparation of 100 mM Na 2 CO 3 solution and 100 mM NaHCO 3 , according to the volume ratio Na 2 CO 3 ∶NaHCO 3 =3:7 to adjust pH to 9.5 and store at room temperature until use. The 20 mM test compound dissolved in 100% DMSO was serially diluted with 100% DMSO to 2000, 500, 125, 31.25, 7.8125, 0.488281, 0.12207, 0.030518, 0.007629 μM, the blank well was 100% DMSO, and then diluted 20 times in C3 reaction buffer (PBS pH 7.4, 1 mM MgCl 2 , 0.05% CHAPS). C3 protein cleavage reaction: In a 96-well white half-well plate, prepare 10 μL of the reaction system in C3 reaction buffer (PBS pH 7.4, 1 mM MgCl 2, 0.05% CHAPS) was added with CVF:Bb at a final concentration of 2nM, 1μL of the test compound diluted in C3 reaction buffer and DMSO, and incubated at room temperature for 1 hour. The final concentrations of the test compounds were 10000, 2500, 625, 156.25, 39.0625, 9.765625, 2.441406, 0.6103515, and 0.152588nM, respectively. Human complement factor C3 was added to the reaction system at a final concentration of 500nM, mixed and reacted in a 37°C incubator for 2 hours. The reaction wells containing only 500nM human complement factor C3 in the reaction mixture were used as negative controls. 97μL of carbonate buffer (pH9.5) was added to a 96-well black adsorption plate, 3μL of C3 protein shearing reaction mixture was added to each well, mixed and sealed, and incubated overnight at 4°C. C3a des Arg detection: Wash the plate three times with 300 μL / well TBST (0.05% Tween 20) solution, add 300 μL StartingBlock TM T20 (TBS) blocking buffer, incubate at 37°C for 5 minutes; wash the plate 3 times with 300 μL / well PBST solution, dilute anti-C3a / C3a des Arg antibody

[2991] in PBST solution at 1:1000, add 100 μL to each well, and incubate at 37°C for 1 hour; wash the plate 3 times with 300 μL / well PBST solution, dilute goat anti-mouse IgG H&L (Goat Anti-Mouse IgG H&L) (HRP) antibody in PBST solution at 1:5000, add 100 μL to each well, and incubate at 37°C for 30 minutes; prepare QuantaBlu TM Fluorescent peroxidase substrate kit (QuantaBlu TM Fluorogenic Peroxidase Substrate Kit) substrate, 1 part of QuantaBlu TM Stable peroxide solution (QuantaBlu TM Stable Peroxide Solution) diluted to 9 parts QuantaBlu TM Substrate solution (QuantaBlu TM Substrate Solution); wash the plate 3 times with 300 μL / well PBST solution, and dry the plate in the last wash; add 100 μL substrate to each well and incubate at room temperature for 20 minutes; add Add 100 μL QuantaBlu TM Stop solution (QuantaBlu TMAfter adding Stop Solution), read the fluorescence value on Flexstation, set the excitation wavelength Ex 320nM, emission wavelength Em 460nM, and Cutoff 455. The inhibition rate was calculated using the following formula: Inhibition rate = {1-(RFU 受试化合物 -RFU 阴性对照孔 ) / (RFU 空白孔 -RFU 阴性对照孔 )}×100% The inhibition curve was drawn based on the concentrations of the compounds and the corresponding inhibition rates using Graphpad Prism software, and the concentration of the compound when the inhibition rate reached 50%, i.e., IC 50 value. Conclusion: The IC value of compound I for the inhibitory activity against Factor B enzyme is 50 The concentration of 1.3nM has a good inhibitory effect on Factor B enzyme. Example 3. Preparation of maleate salt I crystal form About 8 mg of compound I was weighed and dissolved in 0.2 mL of acetonitrile. Maleic acid solution (2 mol / L, 9.8 μL) was added. The mixture was slurried at room temperature overnight. 0.6 mL of isopropyl ether was added and stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. The product was defined as maleate I crystal form by X-ray powder diffraction detection, and the XRPD spectrum is shown in Figure 1, and the positions of its characteristic peaks are shown in Table 1. The DSC spectrum shows that the endothermic peak value is 156.79°C. The TGA spectrum shows that the weight loss is 3.22% at 30°C-145°C. Table 1 Peak position of maleate I crystal form Example 4. Preparation of Phosphate I Crystalline Form About 8 mg of compound I was weighed, 0.2 mL of acetonitrile was added, phosphoric acid solution (2 mol / L, 9.8 μL) was added, and the mixture was stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. The product was defined as phosphate I crystal form by X-ray powder diffraction detection. The XRPD spectrum is shown in Figure 2. Its characteristic peaks are The positions are shown in Table 2. The DSC spectrum shows that the exothermic peak is 195.83°C. The TGA spectrum shows that the weight loss is 2.80% at 30°C-150°C. Table 2 Phosphate I crystal peak position Example 5. Preparation of Phosphate I Crystalline Form About 8 mg of compound I was weighed, 0.2 mL of acetone was added, phosphoric acid solution (2 mol / L, 9.8 μL) was added, and the mixture was stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. X-ray powder diffraction analysis showed that the product was phosphate I crystal form. Example 6. Preparation of Phosphate II Crystalline Form About 8 mg of compound I was weighed, 0.2 mL of ethyl acetate was added, and a phosphoric acid ethanol solution (2 mol / L, 9.8 μL) was added. The mixture was stirred for crystallization, and the solid was vacuum dried after centrifugation to obtain the product. The product was defined as phosphate II crystal form by X-ray powder diffraction detection, and the XRPD spectrum was shown in FIG3 , and the characteristic peak positions were shown in Table 3. The phosphate ion content was 17.33% by ion chromatography. The DSC spectrum showed that the endothermic peak value was 146.30°C. The TGA spectrum showed that the weight loss was 1.09% at 30°C-175°C. Table 3 Phosphate II crystal peak position Example 7. Preparation of Phosphate II Crystalline Form About 40 mg of compound I was weighed, 0.75 mL of acetone was added, phosphoric acid solution (2 mol / L, 47 μL) was added, and the mixture was stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. X-ray powder diffraction analysis showed that the product was phosphate II crystal form. Example 8. Preparation of Phosphate III Crystalline Form About 8 mg of compound I was weighed, 0.2 mL of isopropanol was added, and a phosphoric acid ethanol solution (2 mol / L, 9.8 μL) was added. The mixture was stirred for crystallization, and the solid was vacuum dried after centrifugation to obtain the product. The product was defined as phosphate III crystal form by X-ray powder diffraction detection, and the XRPD spectrum is shown in FIG4 , and the characteristic peak positions are shown in Table 4. The phosphate ion content was 16.72% by ion chromatography. The DSC spectrum showed that the endothermic peaks were 66.14°C and 143.48°C, and the exothermic peak was 182.62°C. The TGA spectrum showed that the weight loss was 6.16% at 30°C-150°C. DVS test shows that under normal storage conditions (i.e. 25°C, 60% RH), the sample has a moisture absorption weight gain of about 4.77%; under accelerated test conditions (i.e. 70% RH), the moisture absorption weight gain is about 5.44%; under extreme conditions (i.e. 90% RH), the moisture absorption weight gain is about 7.20%. After DVS test, the crystal form was retested and the crystal form did not change. Table 4 Phosphate III crystal peak position Example 9. Preparation of Phosphate IV Crystalline Form About 30 mg of compound I was weighed and dissolved in 0.5 mL of acetonitrile. The temperature was raised to 40° C., 8.2 mg of 85% phosphoric acid was added, the mixture was cooled to room temperature and stirred for 16 hours, the filter cake was collected by filtration, and vacuum dried at 60° C. for 4 hours to obtain the product. The product was defined as phosphate IV crystal form by X-ray powder diffraction detection. The XRPD spectrum is shown in FIG5 , and the positions of its characteristic peaks are shown in Table 5. Table 5 Phosphate IV crystal peak position Example 10. Preparation of Phosphate V Crystalline Form 30 mg of compound I was weighed and dissolved in 1 mL of ethanol. The temperature was raised to 40° C., 85% phosphoric acid (8.2 mg, 66.88 μmol) was added, the mixture was cooled to room temperature, stirred for 16 hours, filtered and the filter cake was collected, and vacuum dried at 60° C. for 4 hours to obtain the product. The product was defined as phosphate V crystal form by X-ray powder diffraction detection, and the XRPD spectrum is shown in FIG6 , and the characteristic peak positions are shown in Table 6. The DSC spectrum shows that the endothermic peaks are 48.64°C and 223.41°C, and the exothermic peak is 194.80°C. The TGA spectrum shows that the weight loss is 2.47% from 30°C to 100°C, and the weight loss is 2.76% from 100°C to 250°C. Table 6 Phosphate V crystal peak position Example 11. Preparation of p-toluenesulfonate I Crystalline Form About 8 mg of compound I was weighed and dissolved in 0.2 mL of ethanol. p-Toluenesulfonic acid solution (2 mol / L, 9.8 μL) was added and stirred overnight. 0.8 mL of isopropyl ether was added and stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. The product was defined as p-toluenesulfonate I crystal form by X-ray powder diffraction detection, and the XRPD spectrum was shown in FIG7 , and the characteristic peak positions were shown in Table 7. The ion content of p-toluenesulfonate was 30.75% by ion chromatography. The DSC spectrum showed that the endothermic peaks were 57.15°C and 180.78°C. The TGA spectrum showed that the weight loss was 2.07% at 30°C-145°C. DVS test shows that under normal storage conditions (i.e. 25°C, 60% RH), the sample has a moisture absorption weight gain of about 1.22%; under accelerated test conditions (i.e. 70% RH), the moisture absorption weight gain is about 1.37%; under extreme conditions (i.e. 90% RH), the moisture absorption weight gain is about 1.87%. After DVS test, the crystal form was retested and the crystal form did not change. Table 7 Peak position of p-toluenesulfonate I crystal form Example 12. Preparation of p-toluenesulfonate I Crystalline Form Compound I was weighed, added with a solvent and a 2 mol / L p-toluenesulfonic acid solution, and crystallized to obtain a product. The crystal form was determined by X-ray powder diffraction, as shown in Table 8. Table 8 Preparation of p-toluenesulfonate I crystal form Example 13. Preparation of p-toluenesulfonate II crystalline form About 938 mg of compound I was weighed and dissolved in 40 mL of isopropanol. The solution was stirred at 40 °C and dissolved. The temperature was raised to 60 °C and 398 mg of p-toluenesulfonic acid monohydrate was added. The mixture was stirred for 1 hour and then cooled to room temperature. The filter cake was collected by filtration and dried in vacuo at 60 °C for 4 hours to obtain the product. The product was defined as p-toluenesulfonate II crystal form by X-ray powder diffraction detection. The XRPD spectrum is shown in FIG8 , and the characteristic peak positions are shown in Table 9. The DSC spectrum shows that the endothermic peaks are 104.06°C and 181.38°C, and the exothermic peak is 188.49°C. The TGA spectrum shows that the weight loss is 3.36% from 40°C to 160°C, and the weight loss is 3.84% from 160°C to 270°C. Table 9 p-Toluenesulfonate II crystal peak position Example 14. Preparation of p-toluenesulfonate III crystalline form 15 mg of p-toluenesulfonate II crystalline compound was dispersed in 1 mL of methyl tert-butyl ether and stirred for 72 hours. The filter cake was collected by filtration and dried under vacuum at 60° C. for 4 hours to obtain the product. The product was defined as p-toluenesulfonate III crystalline form by X-ray powder diffraction detection. The XRPD spectrum is shown in FIG9 , and the positions of its characteristic peaks are shown in Table 10. Table 10 p-Toluenesulfonate III crystal peak position Example 15. Preparation of Sulfate Crystal Form I About 8 mg of compound I was weighed, 0.2 mL of acetonitrile was added, sulfuric acid solution (2 mol / L, 9.8 μL) was added, and the mixture was stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. The product was defined as sulfate I crystal form by X-ray powder diffraction detection, and the XRPD spectrum is shown in Figure 10, and the characteristic peak positions are shown in Table 11. The DSC spectrum shows that the endothermic peaks are 52.82°C and 105.48°C, and the exothermic peak is 190.22°C. The TGA spectrum shows that the weight loss is 6.02% from 30°C to 195°C. Table 11 Sulfate I crystal peak position Example 16. Preparation of Sulfate Form I About 8 mg of compound I was weighed, 0.2 mL of ethanol was added, sulfuric acid solution (2 mol / L, 9.8 μL) was added, and the mixture was stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. The product was defined as sulfate I crystal form by X-ray powder diffraction analysis. Example 17. Preparation of Sulfate II Crystalline Form About 8 mg of compound I was weighed, 0.2 mL of acetone was added, sulfuric acid solution (2 mol / L, 9.8 μL) was added, and the mixture was stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. The product was defined as sulfate II crystal form by X-ray powder diffraction detection, and the XRPD spectrum is shown in Figure 11, and the characteristic peak positions are shown in Table 12. The DSC spectrum shows that the endothermic peak value is 64.63°C and the exothermic peak value is 207.53°C. The TGA spectrum shows that the weight loss is 6.12% from 30°C to 180°C. Table 12 Sulfate II crystal peak position Example 18. Preparation of Sulfate III Crystalline Form About 40 mg of compound I was weighed and dissolved in 0.75 mL of ethanol. A sulfuric acid solution (2 mol / L, 47 μL) was added, and 1 mL of isopropyl ether was added. The mixture was stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. The product was defined as sulfate III crystal form by X-ray powder diffraction detection, and the XRPD spectrum was shown in FIG12 , and the characteristic peak positions were shown in Table 13. The sulfate ion content was 15.31% by ion chromatography. The DSC spectrum showed that the endothermic peaks were 76.24°C and 150.06°C. The TGA spectrum showed that the weight loss was 4.31% at 30°C-140°C. Table 13 Sulfate III crystal peak position Example 19. Preparation of sulfate IV crystal form About 8 mg of compound I was weighed, 0.2 mL of isopropanol was added, and a sulfuric acid ethanol solution (2 mol / L, 9.8 μL) was added. The mixture was stirred for crystallization, and the solid was vacuum dried after centrifugation to obtain the product. The product was defined as sulfate IV crystal form by X-ray powder diffraction detection. The XRPD spectrum is shown in Figure 13. The peak positions are shown in Table 14. The ion content of sulfate was 15.72% as determined by ion chromatography. The DSC spectrum showed that the endothermic peaks were 68.75°C and 161.89°C. The TGA spectrum showed that the weight loss was 3.74% at 30°C-135°C. Table 14 Sulfate IV Crystalline Peak Position Example 20. Preparation of sulfate IV crystal form About 40 mg of compound I was weighed, 0.75 mL of acetone was added, sulfuric acid solution (2 mol / L, 47 μL) was added, and the mixture was stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. X-ray powder diffraction analysis showed that the product was sulfate IV crystal form. Example 21. Preparation of sulfate V crystal form About 8 mg of compound I was weighed, 0.2 mL of ethyl acetate was added, and sulfuric acid ethanol solution (2 mol / L, 9.8 μL) was added. The mixture was stirred for crystallization, and the solid was vacuum dried after centrifugation to obtain the product. The product was defined as sulfate V crystal form by X-ray powder diffraction detection, and the XRPD spectrum was shown in FIG14 , and the characteristic peak positions were shown in Table 15. The ion content of sulfate was 11.65% by ion chromatography. The DSC spectrum showed that the endothermic peaks were 61.82°C and 153.47°C. The TGA spectrum showed that the weight loss was 4.19% at 30°C-90°C and 6.18% at 90°C-195°C. Table 15 Sulfate V Crystalline Peak Position Example 22. Preparation of sulfate V crystal form About 500 mg of compound I was weighed and suspended in 20 mL of isopropyl acetate. 109 mg of sulfuric acid was added under stirring at room temperature. The mixture was stirred for 16 hours, filtered, and the filter cake was collected. The product was dried under vacuum at 60° C. for 4 hours to obtain the product. Example 23. Preparation of Sulfate VI Crystalline Form 15 mg of the sulfate salt form I of compound I was weighed and dispersed in 1 mL of isopropyl acetate, stirred at room temperature for 48 hours, filtered and the filter cake was collected, and vacuum dried at 60° C. for 4 hours to obtain the product. The product was defined as sulfate VI crystal form by X-ray powder diffraction detection. The XRPD spectrum is shown in FIG15 , and the positions of its characteristic peaks are shown in Table 16. Table 16 Sulfate VI Crystalline Peak Position Example 24. Preparation of Hydrochloride Form I About 8 mg of compound I was weighed and dissolved in 0.2 mL of ethanol. A hydrochloric acid solution (2 mol / L, 9.8 μL) was added and stirred overnight. 1.0 mL of isopropyl ether was added and stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. The product was defined as hydrochloride I crystal form by X-ray powder diffraction detection, and the XRPD spectrum is shown in Figure 16, and the characteristic peak positions are shown in Table 17. The chloride ion content was 5.94% by ion chromatography. The DSC spectrum showed that the exothermic peak value was 211.63°C. The TGA spectrum showed that the weight loss was 5.62% at 30°C-175°C. Table 17 Hydrochloride I Crystalline Peak Position Example 25. Preparation of Hydrochloride II Crystalline Form About 8 mg of compound I was weighed, 0.2 mL of acetonitrile was added, and a hydrochloric acid solution (2 mol / L, 9.8 μL) was added. The mixture was stirred for crystallization, and the solid was vacuum dried after centrifugation to obtain the title product. The product was defined as hydrochloride II crystal form by X-ray powder diffraction detection, and the XRPD spectrum was shown in FIG17 , and the characteristic peak positions were shown in Table 18. The chloride ion content was 6.94% by ion chromatography. The DSC spectrum showed that the endothermic peak value was 47.48°C and the exothermic peak value was 221.46°C. The TGA spectrum showed that the weight loss was 3.32% at 30°C-165°C. DVS test shows that under normal storage conditions (i.e. 25°C, 60% RH), the sample has a moisture absorption weight gain of about 3.93%; under accelerated test conditions (i.e. 70% RH), the moisture absorption weight gain is about 4.28%; under extreme conditions (i.e. 90% RH), the moisture absorption weight gain is about 5.00%. After DVS test, the crystal form was retested and the crystal form did not change. Table 18 Hydrochloride II Crystalline Peak Position Example 26. Preparation of Hydrochloride II Crystalline Form Compound I was weighed, added with a solvent and a 2 mol / L hydrochloric acid solution, and crystallized to obtain a product. The crystal form was determined by X-ray powder diffraction, as shown in Table 19. Table 19 Preparation of hydrochloride II crystal form Example 27. Preparation of Hydrochloride III Crystalline Form About 8 mg of compound I was weighed, 0.2 mL of acetone was added, and a hydrochloric acid solution (2 mol / L, 9.8 μL) was added. The mixture was stirred for crystallization, and the solid was vacuum dried after centrifugation to obtain the product. The product was defined as hydrochloride III crystal form by X-ray powder diffraction detection, and the XRPD spectrum was shown in FIG18 , and the characteristic peak positions were shown in Table 20. The chloride ion content was 6.68% by ion chromatography. The DSC spectrum showed that the exothermic peak value was 191.78°C and the endothermic peak value was 206.27°C. The TGA spectrum showed that the weight loss was 2.34% at 30°C-155°C. DVS test shows that under normal storage conditions (i.e. 25°C, 60% RH), the sample has a moisture absorption weight gain of about 2.57%; under accelerated test conditions (i.e. 70% RH), the moisture absorption weight gain is about 2.96%; under extreme conditions (i.e. 90% RH), the moisture absorption weight gain is about 4.57%. After DVS test, the crystal form was retested and the crystal form did not change. Table 20 Hydrochloride III Crystalline Peak Position Example 28. Preparation of Hydrochloride III Crystalline Form About 120 mg of compound I was weighed, 3 mL of ethyl acetate was added, and a hydrochloric acid ethanol solution (2 mol / L, 140 μL) was added. The mixture was stirred for crystallization, and the solid was vacuum dried after centrifugation to obtain the product. X-ray powder diffraction analysis showed that the product was hydrochloride III crystal form. Example 29. Preparation of Hydrochloride IV Crystalline Form About 8 mg of compound I was weighed and dissolved in 0.2 mL of tetrahydrofuran. A hydrochloric acid solution (2 mol / L, 9.8 μL) was added and stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. The product was defined as hydrochloride IV crystal form by X-ray powder diffraction detection, and the XRPD spectrum is shown in Figure 19, and the characteristic peak positions are shown in Table 21. The DSC spectrum shows that the exothermic peak value is 208.82°C. The TGA spectrum shows that the weight loss is 2.60% at 30°C-160°C. Table 21 Hydrochloride IV Crystalline Peak Position Example 30. Preparation of Hydrochloride Form V About 140 mg of compound I was weighed and dissolved in 5 mL of acetonitrile. 33 mg of concentrated hydrochloric acid was added under stirring. The mixture was stirred for 16 hours, and the filter cake was collected by filtration. The product was dried under vacuum at 60° C. for 4 hours. The product was defined as hydrochloride V crystal form by X-ray powder diffraction detection. The XRPD spectrum is shown in FIG20 , and the positions of its characteristic peaks are shown in Table 22. The DSC spectrum shows that the peak value of the endothermic peak is 63.15℃, and the peak value of the exothermic peak is 196.81℃ and 211.82℃. The TGA spectrum shows that the weight loss is 4.60% from 30℃ to 170℃, and 6.81% from 170℃ to 260℃. The DVS data shows that under normal storage conditions (i.e. 25℃, 60%RH), the sample has a moisture absorption weight gain of about 6.36%; under accelerated test conditions (i.e. 70%RH), the moisture absorption weight gain is about 7.28%; under extreme conditions (90%RH), the moisture absorption weight gain is about 8.32%. The XRPD spectrum shows that the crystal form of the sample has not changed before and after DVS. Table 22 Hydrochloride V Crystal Form XRPD Data Table Example 31. Preparation of Hydrochloride VI Crystalline Form About 140 mg of compound I was weighed and dissolved in 5 mL of isopropanol. 78 μL of 4 M dioxane hydrochloride solution was added under stirring. The mixture was stirred for 16 hours, filtered and the filter cake was collected, and dried under vacuum at 60°C for 4 hours to obtain the product. The product was defined as hydrochloride VI crystal form by X-ray powder diffraction detection. The XRPD spectrum is shown in Figure 21, and the characteristic peak positions are shown in Table 23. The DSC spectrum shows that the exothermic peaks are 104.31°C, 198.49°C and 204.67°C. The TGA spectrum shows that the weight loss is 3.22% from 30°C to 195°C, and 4.49% from 195°C to 265°C. The DVS data show that under normal storage conditions (i.e., 25°C, 60% RH), the sample has a moisture absorption weight gain of about 3.69%; under accelerated test conditions (i.e., 70% RH), the moisture absorption weight gain is about 4.12%; under extreme conditions (90% RH), the moisture absorption weight gain is about 5.73%. The XRPD spectrum shows that the crystal form of the sample has not changed before and after DVS. Table 23 Hydrochloride VI Crystal Form XRPD Data Table Example 32. Preparation of Fumarate I Crystalline Form About 8 mg of compound I and about 2.27 mg of fumaric acid were weighed, 0.2 mL of acetonitrile was added, and the mixture was stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. The product was defined as fumarate I crystal form by X-ray powder diffraction detection, and the XRPD spectrum was shown in FIG22 , and the characteristic peak positions were shown in Table 24. The ion content of fumarate was 20.34% by ion chromatography. The DSC spectrum showed that the endothermic peak value was 179.08° C. The TGA spectrum showed that the weight loss was 1.02% at 30° C.-150° C. DVS test shows that under normal storage conditions (i.e. 25°C, 60% RH), the sample has a moisture absorption weight gain of about 0.51%; under accelerated test conditions (i.e. 70% RH), the moisture absorption weight gain is about 0.60%; under extreme conditions (i.e. 90% RH), the moisture absorption weight gain is about 0.82%. After DVS test, the crystal form was retested and the crystal form did not change. Table 24 Fumarate I Crystalline Peak Position Example 33. Preparation of Fumarate I Crystalline Form About 80 mg of compound I was weighed and added to a methanol solution of fumaric acid (0.33 mol / L, 537 μL), and 1.5 mL of acetonitrile was added. The mixture was stirred for crystallization, and the solid was vacuum dried after centrifugation to obtain the product. X-ray powder diffraction analysis showed that the product was fumarate I crystalline form. Example 34. Preparation of Fumarate II Crystalline Form About 8 mg of compound I and 2.27 mg of fumaric acid were weighed, dissolved in 0.2 mL of methanol / acetonitrile (V / V=1:8), filtered, evaporated and crystallized to obtain the product. The product was defined as fumarate II crystalline form by X-ray powder diffraction analysis. The XRPD spectrum is shown in FIG23 , and the positions of its characteristic peaks are shown in Table 25. Table 25 Fumarate II Crystalline Peak Position Example 35. Preparation of Hydrobromide Form I About 8 mg of compound I was weighed and dissolved in 0.2 mL of ethanol. Hydrobromic acid solution (2 mol / L, 9.8 μL) was added and stirred overnight. 0.8 mL of isopropyl ether was added and stirred for crystallization. After centrifugation, the solid was vacuum dried to obtain the product. The product was defined as hydrobromide I crystal form by X-ray powder diffraction detection, and the XRPD spectrum is shown in FIG24 , and the characteristic peak positions are shown in Table 26. The bromide ion content was 13.98% by ion chromatography. The DSC spectrum showed that the exothermic peak value was 216.67° C. The TGA spectrum showed that the weight loss was 1.24% at 30° C.-160° C. Table 26 Hydrobromide I Crystalline Peak Position Example 36. Preparation of Hydrobromide II Crystalline Form Weigh about 8 mg of compound I, add 0.2 mL of isopropanol, add hydrobromic acid ethanol solution (2 mol / L, 9.8 μL), stir to crystallize, centrifuge and vacuum dry the solid to obtain the title product. The product was defined as hydrobromide II crystal form by X-ray powder diffraction detection, and the XRPD spectrum was shown in FIG25 , and the characteristic peak positions were shown in Table 27. The bromide ion content was 14.89% by ion chromatography. The DSC spectrum showed that the exothermic peak value was 211.47° C. The TGA spectrum showed that the weight loss was 0.77% at 30° C.-145° C. Table 27 Hydrobromide II Crystalline Peak Position Example 37. Preparation of Hydrobromide Salt II Crystalline Form About 8 mg of compound I was weighed, 0.2 mL of ethyl acetate was added, and a hydrobromic acid ethanol solution (2 mol / L, 9.8 μL) was added. The mixture was stirred for crystallization, and the solid was vacuum dried after centrifugation to obtain the title product. X-ray powder diffraction analysis showed that the product was hydrobromide II crystal form. Example 38. Preparation of amorphous maleate About 8 mg of compound I was weighed and dissolved in 0.2 mL of ethanol. Maleic acid solution (2 mol / L, 9.8 μL) was added. The mixture was slurried at room temperature overnight. 0.6 mL of isopropyl ether was added and stirred to precipitate. After centrifugation, the solid was vacuum dried to obtain the product. X-ray powder diffraction analysis showed that the product was amorphous maleate. Example 39. Preparation of amorphous maleate Compound I was weighed, added with solvent and 2 mol / L maleic acid solution, and crystallized to obtain a product. The crystal form was determined by X-ray powder diffraction, as shown in Table 28. Table 28 Preparation of maleate amorphous Example 40. Preparation of amorphous phosphate About 8 mg of compound I was weighed and dissolved in 0.2 mL of ethanol. A phosphoric acid solution (2 mol / L, 9.8 μL) was added and stirred to precipitate. After centrifugation, the solid was vacuum dried to obtain the product. X-ray powder diffraction analysis showed that the product was amorphous phosphate. Example 41. Preparation of amorphous phosphate Compound I was weighed, added with a solvent and a 2 mol / L phosphoric acid solution, and crystallized to obtain a product. The crystal form was determined by X-ray powder diffraction, as shown in Table 29. Table 29 Preparation of phosphate amorphous Example 42. Preparation of amorphous p-toluenesulfonate About 8 mg of compound I was weighed, 0.2 mL of acetonitrile was added, p-toluenesulfonic acid solution (2 mol / L, 9.8 μL) was added, slurried at room temperature overnight, 0.6 mL of isopropyl ether was added, stirred to precipitate, and the solid was vacuum dried after centrifugation to obtain the product. X-ray powder diffraction analysis showed that the product was amorphous p-toluenesulfonate. Example 43. Preparation of amorphous p-toluenesulfonate Compound I was weighed, added with a solvent and a 2 mol / L p-toluenesulfonic acid solution, and crystallized to obtain a product. The crystal form was determined by X-ray powder diffraction, as shown in Table 30. Table 30 Preparation of p-toluenesulfonate amorphous Example 44. Preparation of Sulfate Amorphous Form About 8 mg of compound I was weighed and dissolved in 0.2 mL of tetrahydrofuran. A sulfuric acid solution (2 mol / L, 9.8 μL) was added. The mixture was slurried at room temperature overnight and stirred to precipitate. After centrifugation, the solid was vacuum dried to obtain the product. X-ray powder diffraction analysis showed that the product was amorphous sulfate. Example 45. Preparation of Sulfate Amorphous Form About 8 mg of compound I was weighed and dissolved in 0.2 mL of acetonitrile / methanol (V / V=1:1). A sulfuric acid solution (2 mol / L, 9.8 μL) was added and slurried at room temperature overnight. 1 mL of isopropyl ether was added and stirred to precipitate. After centrifugation, the solid was vacuum dried to obtain the product. X-ray powder diffraction analysis showed that the product was amorphous sulfate. Example 46. Preparation of amorphous tartrate About 8 mg of compound I was weighed, 0.2 mL of acetonitrile was added, tartaric acid solution (2 mol / L, 9.8 μL) was added, and the mixture was stirred to precipitate. After centrifugation, the solid was vacuum dried to obtain the product. X-ray powder diffraction analysis showed that the product was an amorphous tartrate. Example 47. Preparation of amorphous tartrate Compound I was weighed, added with solvent and 2 mol / L tartaric acid solution, and crystallized to obtain a product. The crystal form was determined by X-ray powder diffraction detection, as shown in Table 31. Table 31 Preparation of tartrate amorphous Example 48. Preparation of amorphous succinate About 8 mg of compound I and about 2.3 mg of succinic acid were weighed, 0.2 mL of acetonitrile was added, and the mixture was slurried at room temperature overnight. After centrifugation, the solid was vacuum dried to obtain the product. X-ray powder diffraction analysis showed that the product was amorphous succinate. Example 49. Preparation of amorphous succinate Compound I was weighed, added with solvent and succinic acid, and crystallized to obtain a product. The crystal form was determined by X-ray powder diffraction, as shown in Table 32. Table 32 Preparation of succinate amorphous Example 50. Preparation of amorphous fumarate About 8 mg of compound I and about 2.3 mg of fumaric acid were weighed, 0.2 mL of acetone was added, and the mixture was slurried at room temperature overnight. After centrifugation, the solid was vacuum dried to obtain the product. X-ray powder diffraction analysis showed that the product was amorphous fumarate, and the XRPD spectrum was shown in FIG26 . Example 51. Preparation of amorphous fumarate Compound I was weighed, a solvent and fumaric acid were added, and the product was crystallized. The crystal form was determined by X-ray powder diffraction, as shown in Table 33. Table 33 Preparation of Fumarate Amorphous Example 52. Preparation of amorphous citrate About 8 mg of compound I was weighed and dissolved in 0.2 mL of ethanol. A citric acid solution (2 mol / L, 9.8 μL) was added. The mixture was slurried at room temperature overnight. 0.6 mL of isopropyl ether was added and stirred to precipitate. After centrifugation, the solid was vacuum dried to obtain the product. X-ray powder diffraction analysis showed that the product was amorphous citrate. Example 53. Preparation of amorphous citrate Compound I was weighed, added to a solvent and a 2 mol / L citric acid solution, and crystallized to obtain a product. The crystal form was determined by X-ray powder diffraction, as shown in Table 34. Table 34 Preparation of Citrate Amorphous Example 54. Preparation of amorphous malate About 8 mg of compound I was weighed and dissolved in 0.2 mL of ethanol. Malic acid solution (2 mol / L, 9.8 μL) was added and slurried at room temperature overnight. 0.6 mL of isopropyl ether was added and stirred to precipitate. After centrifugation, the solid was vacuum dried to obtain the product. X-ray powder diffraction analysis showed that the product was amorphous malate. Example 55. Preparation of amorphous malate Compound I was weighed, added to a solvent and a 2 mol / L malic acid solution, and crystallized to obtain a product. The crystal form was determined by X-ray powder diffraction, as shown in Table 35. Table 35 Preparation of malate amorphous Example 56. Preparation of amorphous hydrobromide About 8 mg of compound I was weighed, 0.2 mL of acetonitrile was added, hydrobromic acid solution (2 mol / L, 9.8 μL) was added, slurried at room temperature overnight, 0.4 mL of isopropyl ether was added, stirred to precipitate, and the solid was vacuum dried after centrifugation to obtain the product. X-ray powder diffraction analysis showed that the product was an amorphous hydrobromide. Example 57. Preparation of amorphous hydrobromide Compound I was weighed, added with a solvent and a 2 mol / L hydrobromic acid solution, and crystallized to obtain a product. The crystal form was determined by X-ray powder diffraction, as shown in Table 36. Table 36 Preparation of hydrobromide amorphous Example 58. Preparation of amorphous mesylate About 8 mg of compound I was weighed, 0.2 mL of acetonitrile was added, methanesulfonic acid solution (2 mol / L, 9.8 μL) was added, slurried at room temperature overnight, 0.3 mL of isopropyl ether was added, stirred to precipitate, and the solid was vacuum dried after centrifugation to obtain the product. X-ray powder diffraction analysis showed that the product was amorphous methanesulfonate. Example 59. Preparation of amorphous mesylate Compound I was weighed, added with solvent and 2 mol / L methanesulfonic acid solution, and crystallized to obtain a product. The crystal form was determined by X-ray powder diffraction, as shown in Table 37. Table 37 Preparation of amorphous mesylate Example 60. Preparation of amorphous hydrochloride About 8 mg of compound I was weighed and dissolved in 0.2 mL of ethanol. A hydrochloric acid solution (2 mol / L, 9.8 μL) was added and stirred overnight. 0.8 mL of isopropyl ether was added and stirred to precipitate. After centrifugation, the solid was vacuum dried to obtain the title product. X-ray powder diffraction analysis showed that the product was an amorphous hydrochloride. Experimental Example 1. Study on the stability of factors affecting the crystalline form of p-toluenesulfonate I The p-toluenesulfonate salt form I was laid out in an open state, and the stability of the sample was investigated under conditions of light (4500 Lux), high temperature (40° C., 60° C.), and high humidity (RH 75%, RH 92.5%). The sampling period was 30 days. Table 38 Stability of factors affecting the crystal form of p-toluenesulfonate I Conclusion: Under the conditions of light, high temperature of 40℃ and 60℃, and high humidity of 75% and 92.5% for 30 days, the physical and chemical stability of the p-toluenesulfonate I crystal form is good. Experimental Example 2. Study on the stability of factors affecting the fumarate I crystal form The fumarate salt form I was laid open and placed flat, and the stability of the sample was investigated under light (4500 Lux), high temperature (40° C., 60° C.), and high humidity (RH 75%, RH 92.5%) conditions, and the sampling period was 30 days. Table 39 Factors affecting stability of fumarate I crystal form Conclusion: Under the conditions of light, high temperature of 40℃ and 60℃, and high humidity of 75% and 92.5% for 30 days, the physical and chemical stability of the fumarate salt form I was good. Experimental Example 3. Study on the stability of factors affecting the hydrochloride II crystal form The hydrochloride II crystal form was laid open and placed flat, and the stability of the sample was investigated under light (4500 Lux), high temperature (40° C., 60° C.), and high humidity (RH 75%, RH 92.5%) conditions. The sampling period was 30 days. Table 40 Hydrochloride II Crystal Form Influencing Factors Stability Conclusion: Under light, high temperature of 40℃ and 60℃, high humidity of 75% and 92.5% for 30 days, the hydrochloride II crystal form has good physical stability; the hydrochloride II crystal form has good chemical stability under high humidity conditions. Experimental Example 4. Study on the stability of factors affecting the crystal form of hydrochloride III The hydrochloride III crystal was laid open and placed flat to observe the The stability of samples under (RH 75%, RH 92.5%) conditions, the sampling observation period is 30 days. Table 41 Factors affecting stability of hydrochloride III crystal form Conclusion: Under light, high temperature of 40℃ and 60℃, high humidity of 75% and 92.5% for 30 days, the hydrochloride III crystal form has good physical stability; the hydrochloride III crystal form has good chemical stability under high humidity conditions. Experimental Example 5. Study on the stability of factors affecting the crystal form of phosphate II The phosphate II crystal form was laid out in an open position, and the stability of the sample was investigated under conditions of light (4500 Lux), high temperature (40° C., 60° C.), and high humidity (RH 75%, RH 92.5%). The sampling period was 30 days. Table 42 Factors affecting the stability of phosphate II crystal form Conclusion: Phosphate II crystal form has good chemical stability under high humidity conditions and good physical stability under high temperature, light and high humidity (75% RH) conditions. Experimental Example 6. Long-term accelerated stability study of p-toluenesulfonate I crystal The p-toluenesulfonate salt Form I was sealed and placed under 25°C / 60% RH and 40°C / 75% RH conditions to investigate the stability. Table 43 Long-term / accelerated stability of p-toluenesulfonate Form I Conclusion: Long-term accelerated experiments showed that the p-toluenesulfonate Form I had good physical and chemical stability at 25°C / 60%RH and 40°C / 75%RH for 6 months. Experimental Example 7. Long-term accelerated stability study of fumarate salt form I The fumarate salt form I was sealed and placed under 25°C / 60% RH and 40°C / 75% RH conditions to investigate the stability. Table 44 Long-term / accelerated stability of fumarate salt Form I Conclusion: Long-term accelerated experiments showed that the fumarate salt form I had good physical and chemical stability at 25°C / 60%RH and 40°C / 75%RH for 6 months. Experimental Example 8. Long-term accelerated stability study of hydrochloride II crystal form The hydrochloride salt II crystal was sealed and placed under 25°C / 60% RH and 40°C / 75% RH conditions to investigate the stability. Table 45 Long-term / accelerated stability of hydrochloride II crystal form Conclusion: Long-term accelerated experiments showed that the hydrochloride II crystal form had good physicochemical stability at 25℃ / 60%RH and 40℃ / 75%RH for 6 months. Experimental Example 9. Long-term accelerated stability study of hydrochloride III crystal form The hydrochloride salt III crystal was sealed and placed under 25°C / 60% RH and 40°C / 75% RH conditions to investigate the stability. Table 46 Long-term / accelerated stability of hydrochloride III crystal form Conclusion: Long-term accelerated experiments showed that the hydrochloride III crystal had good physical and chemical stability at 25℃ / 60%RH and 40℃ / 75%RH for 6 months. Experimental Example 10. Study on long-term accelerated stability of phosphate II crystal The phosphate II crystal was sealed and placed under 25°C / 60% RH and 40°C / 75% RH conditions to investigate the stability. Table 47 Long-term / accelerated stability of phosphate II crystal form Conclusion: Long-term accelerated experiments showed that the phosphate II crystal form had good physical stability and long-term chemical stability at 25℃ / 60%RH and 40℃ / 75%RH for 2 months.

Claims

1. A pharmaceutically acceptable salt of 4-((1S, 3S, 5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid, wherein the pharmaceutically acceptable salt is selected from maleate, phosphate, p-toluenesulfonate, sulfate, hydrochloride, fumarate, tartrate, succinate, citrate, malate, methanesulfonate and hydrobromide 。 2. A method for preparing a pharmaceutically acceptable salt of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octane-1-yl)benzoic acid according to claim 1, comprising the step of reacting 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octane-1-yl)benzoic acid with an acid selected from the group consisting of maleic acid, phosphoric acid, p-toluenesulfonic acid, sulfuric acid, hydrochloric acid, fumaric acid, tartaric acid, succinic acid, citric acid, malic acid, methanesulfonic acid and hydrogen peroxide. Bromic acid.

3. The pharmaceutically acceptable salt according to claim 1, It is characterized in that the chemical ratio of 4-((1S, 3S, 5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid to acid is 3:1-1:2, preferably 2:1 -1∶1。 4. A maleate I crystalline form of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is at 6.7, 7.6, 8.6, 11.0, 12.1 and 16. 2; preferably at 6.7, 7.6, 8.1, 8.6, 11.0, 12.1, 16.2, 19.7 and 23.5, more preferably at 6.7, 7.6, 8.1, 8.6, 9.3, 11.0, 12.1, 13.5, 16.2, 17.9, 19.7 and 23.5, most preferably at a diffraction angle 2θ angle X-ray powder diffraction pattern The spectrum is shown in Figure 1.

5. A phosphate crystal form I of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is at 8.4, 10.3, 11.7, 14.8, 19.2 and 21.8 The X-ray powder diffraction pattern is preferably characterized by peaks at 8.4, 10.3, 11.7, 12.5, 14.8, 19.2, 19.8, 21.8 and 23.9, more preferably at 7.0, 8.4, 9.3, 10.3, 11.7, 12.5, 14.8, 17.4, 19.2, 19.8, 21.8 and 23.9, and most preferably at a diffraction angle of 2θ. The radiation spectrum is shown in Figure 2.

6. A phosphate II crystal form of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is at 8.4, 9.5, 10.2, 11.7, 14.7 and 1 9.1, preferably at 6.9, 8.4, 9.5, 10.2, 10.7, 11.7, 14.7, 18.5 and 19.1, more preferably at 6.9, 8.4, 8.8, 9.5, 10.2, 10.7, 11.7, 14.7, 15.7, 18.5, 19.1 and 19.8, most preferably at a diffraction angle of 2θ expressed as X-ray powder The final diffraction pattern is shown in Figure 3.

7. A phosphate III crystal form of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is at 7.0, 8.0, 9.8, 11.5, 18.5 and 2 1.3, preferably at 7.0, 8.0, 9.8, 11.5, 16.1, 18.0, 18.5, 21.3 and 24.1, more preferably at 7.0, 8.0, 9.8, 11.5, 16.1, 18.0, 18.5, 20.8, 21.3, 22.9, 24.1 and 25.3, most preferably at a diffraction angle of 2θ, expressed as an X-ray The powder diffraction pattern is shown in Figure 4.

8. A phosphate IV crystal form of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, having characteristic peaks at 6.9, 8.4, 10.3, 11.7 and 14.8 as shown in an X-ray powder diffraction pattern expressed as a diffraction angle of 2θ, preferably having characteristic peaks at 14.8, 15.7, 16.9, 17.8, 18.9, 19.0, 20.1, 21.3, 22.4, 23.9, 24.7, 25.8, 26.9, 27.9, 28.9, 29.0, 30.9, 31.4, 32.5, 33.7, 34.8, 36.9, 37.9, 38.9, 39.4, 40.5, 41.6, 42.7, 43.9, 44.9, 45.9, 47.9, 48.9, 49.1, 50.1, 51.2, 52.9, 53.9, 54.9, 55.9, 56.9, 57.9, 58.9, 59. -X-ray powder diffraction pattern is shown in Figure 5.

9. A phosphate V crystal form of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 9.1, 10.2, 11.5, 15.7 and 19.8, preferably at 8.6, 9.1, 10.2, 11.5, 15.7, 18.0, 19.8 and 23.5, more preferably expressed as a diffraction angle 2θ The X-ray powder diffraction pattern of is shown in FIG6 .

10. A p-toluenesulfonate salt of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octane-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed at a diffraction angle of 2θ has characteristic peaks at 5.0, 9.4, 10.1, 16.3 and 18.3, preferably at 5.0, 9.4, 10.1, 16.3, 18.3, 18.9, 21.2 and 22.9, more preferably at 5.0, 9.4, 10.1, 16.0, 16.3, 17.1, 18.3, 18.9, 21.2, 22.9 and 24.0, and most preferably at a diffraction angle of 2θ. The X-ray powder diffraction pattern expressed in degrees is shown in FIG7 .

11. A p-toluenesulfonate II crystalline form of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of a diffraction angle 2θ has characteristic peaks at 4.7, 8.8, 9.3, 10.8, 13.9 and 18.7, preferably at 4.7, 8.8, 9.3, 9.7, 10.8, 13.9, 17.7 and 18.7, more preferably at 4.7, 8.8, 9.3, 9.7, 10.8, 13.9, 17.7 and 18.

7. The X-ray powder diffraction pattern expressed in 2θ angle is shown in FIG8 .

12. A crystalline form of p-toluenesulfonate of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 6.8, 7.4, 8.1, 10.1 and 12.7, preferably at The X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in FIG9 .

13. A sulfate crystal form I of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 7.2, 9.2, 17.1, 20.0, 21.4 and 24.7; preferably, it has characteristic peaks at 6.7, 7.2, 9.2, 17.1, 18.7, 20.0, 21.4, 22.9 and 24.7, and more preferably The X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in FIG10 .

14. A sulfate salt II crystal form of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ has characteristic peaks at 9.5, 10.2, 16.6, 21.2 and 25.7; preferably, the crystal form has characteristic peaks at 6.3, 8.5, 9.5, 10.2, 16.6, 19.8, 21.2, 23.7 and 25.7 , more preferably, the X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in FIG11 .

15. A sulfate salt of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid in form III according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ has characteristic peaks at 6.9, 7.6, 9.1, 18.2 and 23.7; preferably, the X-ray powder diffraction pattern has characteristic peaks at 6.9, 7.6, 9.1, 17.0, 18.2, 20.7, 23.7 and 24.

0. The characteristic peaks, more preferably the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ, are shown in FIG. 12 .

16. A sulfate salt of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid in form IV according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ has characteristic peaks at 6.9, 12.5, 16.5, 19.4, 21.2 and 24.0; preferably at 6.9, 9.7, 12.5, 16.5, 19.4, 21.2, 24.0 and 25. 8, and more preferably the X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in FIG13 .

17. A sulfate crystal form V of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, having characteristic peaks at 7.6, 11.4, 13.5, 17.2, 18.8 and 19.5 in an X-ray powder diffraction pattern expressed as a diffraction angle 2θ; preferably at 7.6, 10.0, 11.4, 13.5, 14.0, 17.2, 19.5, 22.5 and 26.

5. There is a characteristic peak at 24.6, and the X-ray powder diffraction pattern represented by the diffraction angle 2θ is more preferably as shown in Figure 14.

18. A sulfate VI crystal form of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ has characteristic peaks at 6.7, 8.8, 14.6, 15.9 and 23.7; preferably at 6.7, 8.8, 10.6, 14.6, 15.9, 19.5, 21 There are characteristic peaks at .4 and 23.7, and more preferably the X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in Figure 15.

19. A hydrochloride form I of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ has characteristic peaks at 5.8, 8.8, 11.6, 20.7 and 23.4; preferably at 5.8, 8.8, 9.8, 10.5, 11.6, 14.6, 18.4 , 20.7 and 23.4, and more preferably, the X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in Figure 16.

20. A hydrochloride II crystal form of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ has characteristic peaks at 5.9, 8.8, 10.6, 17.2, 19.3 and 23.9, preferably at 5.9, 8.8, 10.6, 13.2, 17.2, 19.3, 21.3, 23.9, 24.4 and 26.1, more preferably at 5.9, 8.8, 10.6, 11.9, 13.2, 14.7, 17.2, 19.3, 19.9, 21.3, 23.9, 2 There are characteristic peaks at 4.4, 26.1 and 27.4, and the most preferred X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in FIG17 .

21. A hydrochloride III crystal form of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 6.1, 8.8, 10.4, 18.4, 19.9 and 24.6, preferably at 6.1, 8.8, 10.4, 12.2, 18.4, 19.9, 22.6, 24.6 and 28.0, more preferably at 6.1, 8.8, 10.4, 12.2, 14.6, 16.6, 17.8, 18.4, 19.9, 22. There are characteristic peaks at 6, 24.6, 27.2 and 28.0, and the most preferred X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in FIG18 .

22. A hydrochloride IV crystal form of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, having characteristic peaks at 5.4, 9.0, 10.8, 20.4 and 21.8 in an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, preferably at 5.4, 9.0, 10.8, There are characteristic peaks at 19.3, 20.4, 21.8 and 27.3, and the X-ray powder diffraction pattern represented by the diffraction angle 2θ is more preferably as shown in Figure 19.

23. A hydrochloride form V of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ has characteristic peaks at 5.2, 6.7, 7.7, 10.2 and 17.4, preferably at 5.2, 6.7, 7.7, 10. .2, 10.8, 17.4, 20.5 and 24.2, and more preferably the X-ray powder diffraction pattern expressed in terms of the diffraction angle 2θ is shown in FIG20 .

24. A crystalline form VI of the hydrochloride salt of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is 5. There are characteristic peaks at 8, 10.3, 11.7, 17.7, 20.7 and 23.7, and the X-ray powder diffraction pattern preferably represented by the diffraction angle 2θ is shown in Figure 21.

25. A crystalline form I of the fumarate of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octane-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 9.6, 14.0, 16.7, 19.6, 25.8 and 26.1, preferably at 6.1, 9.6, 10.0, 14.0, 16.7, 17.2, 19.1, 19.6, 25.8 and 26.1, more preferably at 6.1, 9.6, 10.0, 10.8, 14.0, 16.7, 17.2, 1 There are characteristic peaks at 8.6, 19.1, 19.6, 20.2, 25.8 and 26.1, and the most preferred X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in FIG. 22 .

26. A crystal form II of the fumarate of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is 6.2, 6.6, 8.0, 13.2, 14.0 , 20.3 and 24.2; preferably, there are characteristic peaks at 6.2, 6.6, 8.0, 9.0, 13.2, 14.0, 16.4, 17.1, 19.8, 20.3, 24.2 and 25.3; more preferably, there are characteristic peaks at 6.2, 6.6, 8.0, 9.0, 12.0, 13.2, 14.0, 16.4, 17.1, 19.3, 19.8, 20. There are characteristic peaks at 3, 21.9, 22.3, 24.2, 25.3, 25.7 and 28.1, and the most preferred X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in FIG23 .

27. A crystalline form I of the hydrobromide of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octane-1-yl)benzoic acid according to claim 1, having an X-ray powder diffraction pattern expressed in terms of a diffraction angle 2θ, with characteristic peaks at 7.6, 10.6, 16.4, 18.4, 22.6 and 24.0, preferably at 7.6, 10.6, 15.3, 16.4, 18.4, 19.6, 22.6, 24.0, 26.5 and 27.0, more preferably at 7.6, 10.6, 15.3, 16.4, 18.4, 19.6, There are characteristic peaks at 21.4, 22.6, 24.0, 25.5, 26.5, 27.0 and 28.9, and the most preferred X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in FIG. 24 .

28. A crystalline form II of the hydrobromide of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1, wherein the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ has characteristic peaks at 7.2, 10.5, 16.5, 22.5, 23.4 and 26.6, preferably at 7.2, 10.5, 13.1, 16.5, 18.8, 20.3, 22.5, 23.4 and 26.6, more preferably at 7.2, 10.5, 13.1, 16.5, 17 .2, 18.8, 20.3, 21.5, 21.9, 22.5, 23.4 and 26.6, and the most preferred X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG. 25 .

29. A 4-((1S according to any one of claims 4-26. ,3S,5R)-3-ethoxy-8-(( A crystalline form of a pharmaceutically acceptable salt of (5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid, wherein the error range of the 2θ angle is ±0.

2.

30. A pharmaceutical composition comprising the following components: i) 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8- A pharmaceutically acceptable salt of azabicyclo[3.2.1]octan-1-yl)benzoic acid or a crystalline form of a pharmaceutically acceptable salt of the compound represented by formula (I) according to any one of claims 4 to 22; and ii) one or more pharmaceutically acceptable excipients.

31. A method for preparing a pharmaceutical composition, comprising the steps of: treating a pharmaceutically acceptable salt of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1 or a pharmaceutically acceptable salt of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to any one of claims 4 to 29; The step of mixing a crystalline form of a pharmaceutically acceptable salt of 3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid with a pharmaceutically acceptable excipient.

32. A pharmaceutically acceptable salt of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1 or a pharmaceutically acceptable salt of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to any one of claims 4 to 29. [3.2.1] a crystalline form of a pharmaceutically acceptable salt of octan-1-yl)benzoic acid, or the composition according to claim 30, for preparing a medicament for inhibiting activation of the complement alternative pathway, preferably for preparing a medicament for inhibiting complement factor B.

33. A crystalline form of a pharmaceutically acceptable salt of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to claim 1 or a pharmaceutically acceptable salt of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid according to any one of claims 4 to 29 , or use of the composition according to claim 30 in the preparation of a medicament for treating a disease or condition, wherein the disease or condition is selected from glomerulopathy, hemolytic uremic syndrome, atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, geographic atrophy, diabetic retinopathy, uveitis, retinitis pigmentosa, macular edema, uveitis caused by Behcet's syndrome, multifocal choroiditis, Fuku-Koyanagi-Harada syndrome, birdshot retinochoroiditis, sympathetic ophthalmia, ocular cicatricial pemphigoid, ocular pemphigus, nonarteritic ischemic optic neuropathy, postoperative inflammation, retinal vein occlusion, neurological disorders, multiple sclerosis, stroke, Guillain-Barré syndrome, traumatic brain injury, Parkinson's disease, inappropriate or undesired complement activation disorders, complications of hemodialysis, hyperacute allograft rejection, xenograft rejection, interleukin-2-induced toxicity during IL-2 therapy, Crohn's disease, adult respiratory distress syndrome, myocarditis, postischemic reperfusion disorder, myocardial infarction, balloon angioplasty, cardiopulmonary bypass surgery, or renal bypass surgery Post-pump syndrome, atherosclerosis, hemodialysis, renal ischemia, aortic reconstruction, mesenteric artery reperfusion after infectious disease or sepsis, systemic lupus erythematosus, systemic lupus erythematosus nephritis, proliferative nephritis, liver fibrosis, hemolytic anemia, myasthenia gravis, tissue regeneration, nerve regeneration, dyspnea, hemoptysis, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, emphysema, pulmonary embolism and infarction, pneumonia, fibrosing dust disease, pulmonary fibrosis, asthma, allergy, bronchoconstriction, parasitic diseases, Goodman syndrome, lung Vasculitis, pauci-immune vasculitis, immune complex-associated inflammation, antiphospholipid syndrome and obesity; the disease or disorder is preferably C3 glomerulopathy, immunoglobulin A nephropathy, membranous glomerulonephritis, atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria.

Images